<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Tammy Lynn Davis on Medium]]></title>
        <description><![CDATA[Stories by Tammy Lynn Davis on Medium]]></description>
        <link>https://medium.com/@tammylynndavis?source=rss-bea04f141334------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*Ip2KGEA-ZCEkRd4IZ9bz3A.jpeg</url>
            <title>Stories by Tammy Lynn Davis on Medium</title>
            <link>https://medium.com/@tammylynndavis?source=rss-bea04f141334------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Mon, 16 Nov 2026 07:22:49 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@tammylynndavis/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[The Contradiction Is the Invitation]]></title>
            <link>https://tammylynndavis.medium.com/the-contradiction-is-the-invitation-2ea150f7cf30?source=rss-bea04f141334------2</link>
            <guid isPermaLink="false">https://medium.com/p/2ea150f7cf30</guid>
            <category><![CDATA[self-improvement]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[mindfulness]]></category>
            <category><![CDATA[mental-health]]></category>
            <category><![CDATA[holistic-health]]></category>
            <dc:creator><![CDATA[Tammy Lynn Davis]]></dc:creator>
            <pubDate>Sun, 13 Sep 2026 18:34:44 GMT</pubDate>
            <atom:updated>2026-09-13T18:34:44.839Z</atom:updated>
            <content:encoded><![CDATA[<h4>Why the confusion about health is not a problem, but a signal to pay attention to</h4><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*4ZspiqTL5Mr7oqxJbyLoBQ.jpeg" /></figure><p>Fifty years of peer-reviewed research on human health say two things at once. We are living longer than any humans in history, and we are sicker in ways that would have puzzled our grandparents. Heart disease deaths in the United States have fallen by roughly two-thirds since 1970. Obesity has more than doubled worldwide since 1990, and quadrupled in children. Cancer is killing fewer of us every year. Our teenagers are more anxious and more depressed than any cohort we have measured.</p><p><strong>Both statistics (positive and negative) are true</strong>. Neither cancels the other. And if you have felt overwhelmed trying to sort out what to eat, what to take, what to avoid, what to believe, that overwhelm is not a failure of intelligence. It is not only an accurate assessment, but a cry to turn to yourself.</p><h4>What a contradiction actually is</h4><p>The word comes from the Latin <em>contra dicere</em>, to speak against. A contradiction is two voices speaking at the same time. <strong>We have been taught to treat that as noise, something to resolve quickly so we can get back to </strong>certainty. But <strong><em>the body does not work on certainty</em></strong>.</p><p>It works on feedback.</p><p>Every system you have, from blood sugar to body temperature to the immune response, runs on a continuous conversation between signals that pull in opposite directions. <strong>Health is not the absence of contradiction</strong>. Health is the capacity to hear both sides and respond.</p><p>So when the science contradicts itself, when one study says antioxidants protect and the next says they shorten life, when one decade says fat is the enemy and the next says sugar is, the contradiction is not evidence that science has failed. <strong>It is evidence that a living system is being studied by people who are themselves living systems, and that no single voice gets the final word.</strong></p><h4>The trigger, reconsidered</h4><p>We have a word for the moments when the contradiction lands in the body: <em>trigger</em>. The word has an unglamorous origin. It comes from the Dutch <em>trekker</em>, the thing that pulls. Before it named a mechanism on a firearm, it named the act of drawing something toward you.</p><p>I would like to give the word back its original job. A trigger is a pull. It is the inner self tugging at your sleeve, saying: ‘<em>something here needs attention’.</em> The racing thoughts at 3 a.m., the tightness that arrives before you have named the worry, the exhaustion that no amount of sleep touches. These are not malfunctions. They are communication. The body is wired to stay in constant conversation, internally between its own systems and externally with the environment it moves through. It never stops talking. The only question is whether ‘<em>anyone’</em> is listening.</p><p>Attention, incidentally, comes from <em>attendere</em>, to stretch toward. It is not a passive state. It is a reaching.</p><h4>Partnership, not rescue</h4><p>Here is where most of the confusion comes from. <strong>We have been sold a model of health in which the body is a problem and something outside the body is the solution</strong>:</p><ul><li>a pill</li><li>a protocol</li><li>a supplement</li><li>a practitioner</li></ul><p>I call this the Rescue Fallacy, and it is expensive in every sense. It costs money, it costs time, and it costs us the relationship with the one system that has been doing the work all along.</p><p>The research is unusually <strong>clear</strong> on this point, if you read it plainly. The interventions with the strongest evidence in all of medicine are not products.</p><ul><li>exercise</li><li>a Mediterranean-style pattern of eating</li><li>sleep</li><li>human connection</li></ul><p>In the Diabetes Prevention Program, a lifestyle change outperformed a drug, 58 percent to 31 percent, at preventing type 2 diabetes. That is not an argument against medicine. Medicine ran the trial. It is an argument that the body, <strong>when partnered with</strong>, does most of the heavy lifting on its own.</p><p>Partnership is different from rescue. In a partnership, you do not override the other party. You listen, you offer, you notice what changes, and you adjust. The body does not need much. It needs a signal it can recognize.</p><h4>Why plants matter</h4><p>This is where plants come in, and it is worth being precise about why, because the usual explanation is vague to the point of uselessness.</p><p>The precise reason is chemical.</p><ul><li>Aspirin is willow bark</li><li>Morphine is poppy</li><li>Digoxin is foxglove</li><li>Quinine is cinchona.</li><li>Metformin, the most prescribed diabetes drug in the world, descends from a weed called goat’s rue</li><li>Artemisinin, which has saved millions from malaria, is sweet wormwood, and the woman who isolated it won a Nobel Prize in 2015</li></ul><p>The line between “natural” and “pharmaceutical” was never real. It is a marketing category. Plant chemistry is pharmacology, and <strong>pharmacology is plant chemistry that learned to measure itself.</strong></p><p>But there is a second reason, and it is the one nobody says out loud. There is a broad cultural move to reconnect with nature right now. Ask why, and you will hear that it is good for our health, which is true and also empty, the way “eat well” is true and empty. I think the real reason is simpler and stranger. <strong>Connecting with nature reconnects us to ourselves</strong>. We are nature. When we sit with a plant, or breathe the volatile chemistry it releases, we are not visiting something foreign. We are being reminded of a conversation we are already part of.</p><p>An essential oil, in my practice, is a reminder. It does not do the work. It signals a system that already knows how to do the work and has, for whatever reason, stopped attending to it.</p><h4>What no study can promise</h4><p>I want to be careful here, because I am a peer reviewer by trade and I take evidence seriously. No study can guarantee an outcome for you. Not a drug trial, not a diet trial, not a trial of lavender oil. <strong>Studies describe populations</strong>. You are an individual, with your own biochemistry, your own history, and your own way of responding to a signal. My standard is <em>studied, not promised</em>. The research tells us what has been observed. <strong>It does not tell us what will happen when you, specifically, start paying attention</strong>.</p><p>That is not a limitation of science. It is the space where you come in.</p><h4>An invitation</h4><p>If any of this has pulled at you, that pull is the point. You do not need to resolve the contradictions. You need to hear them, and then turn toward the one voice that has been speaking the whole time.</p><p>I teach this. ANIS™ Foundations is a six-month online course, opening January 11, 2027, that begins with a question I take seriously: what the heck is an essential oil, and why does using one matter? It is built for beginners, allied health professionals, and anyone who has decided that partnership with the body is a skill worth learning. Details and registration are at <a href="https://aromagenomics.com/">aromagenomics.com</a>.</p><p>Or simply take the invitation as it stands. The next time something triggers you, try hearing it as a pull instead of a push. Then ask what it is drawing you toward.</p><p><em>Tammy L. Davis, MCN, is a Master Clinical Neuroaromatherapist, the founder of Aromagenomics, and the developer of the ANIS™ (Aromatic Neural Integrative Solutions). She has worked with essential oils for nearly forty years and coached people toward emotional sobriety for twenty.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=2ea150f7cf30" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The twin who didn’t grow breasts …]]></title>
            <link>https://tammylynndavis.medium.com/the-twin-who-didnt-grow-breasts-353dab4c6bdd?source=rss-bea04f141334------2</link>
            <guid isPermaLink="false">https://medium.com/p/353dab4c6bdd</guid>
            <category><![CDATA[natural-medicine]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[environment]]></category>
            <category><![CDATA[medicine]]></category>
            <category><![CDATA[science]]></category>
            <dc:creator><![CDATA[Tammy Lynn Davis]]></dc:creator>
            <pubDate>Mon, 10 Aug 2026 22:20:54 GMT</pubDate>
            <atom:updated>2026-08-10T22:20:54.005Z</atom:updated>
            <content:encoded><![CDATA[<h4>… the trouble with believing ‘the science’ … completely!</h4><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*FuKkE321VvbzB7k6eu8jHQ.jpeg" /></figure><p>In 2007, the New England Journal of Medicine published a brief report describing three prepubertal boys who developed breast tissue. All three were otherwise healthy, with normal serum steroids. All three had been using personal care products said to contain lavender or tea tree oil — a healing balm, a styling gel, a scented soap and lotion. In each case, the gynecomastia resolved after the products were discontinued. The authors ran the oils through in vitro assays, found weak estrogenic and antiandrogenic activity in human cell lines, and concluded that repeated topical exposure had probably caused the breast development.</p><p>One of the boys had a fraternal twin. The twin used the same lavender-scented products, in the same household, and developed nothing.</p><p>That detail is in the original paper. It is not hidden. And in twenty years of increasingly bitter disbelief about this report — an argument that has consumed regulatory attention, industry rebuttals, follow-up studies at a national laboratory, and an entire population of hyper-concerned parents — almost nobody on either side has treated the twin as the clarifying sentence in the case series. <strong>Everyone argued about the oil</strong>. Nobody wanted to talk about the boys.</p><h4>The fight, briefly</h4><p>The rebuttals arrived fast, and some of them landed. The reported estrogenic activity was extraordinarily weak. The products were self-reported and never chemically analyzed; nobody measured what was actually in them or how much reached the skin. Dermal penetration studies suggested the absorbed dose of the relevant constituents would be far too low. A 2024 review ran the full case literature — twelve patients across five publications, all told — through Hill’s criteria for causation and concluded the association was weak and cause-and-effect had not been shown.</p><p>I will note, because my whole argument here is about intellectual hygiene, that several of the loudest early rebuttals came from people with commercial stakes in tea tree and lavender — a conflict they disclosed and their readers mostly ignored. A disclosed conflict is not a refutation of a refutation. But it is context, and <strong>this is a story about what happens when nobody’s context gets examined.</strong></p><p>Then in 2019, the original group’s successors at NIEHS escalated. Ramsey and colleagues added new cases — including premature thelarche in girls, one of whom was exposed by sitting near a diffuser at school — and did something the 2007 paper never did: they tested constituents. Eight of them, the ones ISO mandates for lavender and tea tree oil, in receptor-transfected human cells. Estradiol drove a roughly fifty-fold increase in estrogen-response activity; the whole oils drove about twenty-fold. And the constituents scattered: alpha-terpineol was the most active, terpinen-4-ol and linalool somewhat less, linalyl acetate weaker still, and eucalyptol, limonene, and alpha-terpinene showed essentially nothing.</p><p>Hold that last sentence, because it quietly detonates the terms of the entire debate. If eucalyptol is inert and alpha-terpineol is active, then ‘lavender oil’ was never a single exposure. It is a mixture whose endocrine-relevant chemistry varies with species, chemotype, harvest, and adulteration — which means that for twenty years, <strong>both camps have been arguing about a variable that does not exist.</strong></p><h4>Then the products were finally analyzed</h4><p>It gets better, by which I mean worse. In 2020, letters to the journal reported chemical analyses of the actual products implicated in the new cases. In some of them, linalyl acetate — the signature ester of true lavender — could not be reliably detected at all, and linalool appeared only in trace amounts in one product. <strong>Whatever was making these products smell like lavender, it apparently wasn’t much lavender.</strong></p><p>What one product did contain, at 3.61 percent:</p><blockquote><em>diethyl phthalate — a synthetic compound with a well-documented endocrine-disruption literature of its own (which the case report had filed under ‘unidentified substances.’)</em></blockquote><p>Another contained <strong>Lilial, a suspected endocrine disruptor since banned in EU cosmetics.</strong></p><p>So the strongest recent cases in the ‘lavender disrupts hormones’ file involve products that may have contained little or no lavender, but did contain known synthetic endocrine disruptors that nobody initially looked for. <strong>The critics, meanwhile, raised the possibility that the in vitro assays themselves were contaminated by estrogenic compounds leaching from plastic labware.</strong> At every layer of this controversy, the exposure was assumed rather than characterized. The word ‘lavender’ on a label was treated as ‘beneficial’. It was, and continues to be, marketing.</p><h4>Now, about that twin</h4><p>Here is where I part company with both camps, because the twin discordance cuts in a direction neither of them wants to face. If the products <strong>caused</strong> one boy’s gynecomastia, why not his brother’s? There are two honest answers. Either the lavender products didn’t cause it — prepubertal gynecomastia has a background rate; most cases are labeled idiopathic; and resolution over months proves nothing, as the condition frequently resolves on its own. Or the products affected one boy and not the other, because the boys were different:</p><ul><li>different skin barrier function and absorption</li><li>different steroid metabolism</li><li>different receptor sensitivity</li><li>different everything that makes fraternal twins siblings rather than replicates</li></ul><p>Notice that both answers destroy the same thing: the population-level claim. ‘<em>Lavender causes gynecomastia</em>’ fails either way — either as a false alarm, or as a statement missing its essential qualifier, in a susceptible child, under an exposure nobody measured. The one reading the twin will not support is the one the entire debate was conducted in: that a substance called lavender has a property called endocrine disruption.</p><h4>What the contradiction is telling us</h4><p>I want to be precise about my own position, because this is a case where my field’s instinct — circle the wagons, the oils are fine — deserves as much scrutiny as the alarm. The in vitro receptor activity is real, replicated, and constituent-specific; alpha-terpineol and linalool do things in those assays that eucalyptol does not, and <strong>pretending otherwise is its own evidence</strong>-laundering. Whether that activity survives dermal absorption, systemic dilution, and metabolism to matter in an actual child remains unshown, and the Hill’s-criteria analysis says so plainly. <strong>Weak in vitro signal plus uncharacterized exposure plus twelve heterogeneous case reports is not causation</strong>. It is also ‘not’ nothing. It is a hypothesis that was never tested properly because <strong>no one</strong> characterized either side of the interaction.</p><p>And that is the lesson this file adds to the series. <strong>Installment one argued that the receiving nervous system is a variable our trials refuse to measure.</strong> This one shows the mirror failure: the exposure itself was never measured either. Twenty years, a national laboratory, the world’s most prestigious medical journal — and at no point did anyone establish, at the constituent level, what twelve children actually absorbed, or what distinguished them from the millions of children, including one fraternal twin, who used the same shelf of products and developed nothing. <strong>Both camps treated ‘lavender’ as a monolith and children as interchangeable</strong>. The contradiction was never in the data. It was manufactured by the resolution at which everyone insisted on looking.</p><p><strong>Next in the series: </strong>Linalool — the constituent that showed up in both installments so far — is documented in the literature as a sedative. It is also documented in the literature as doing nothing of the kind, and in some conditions the arrow points the other way. Same molecule, opposite nervous systems. We’ll look at what determines which one shows up.</p><p><em>Tammy L. Davis, MCN, is an instructor at the University of New Mexico and Santa Fe Community College as well as the founder of Aromagenomics and developer of the ANIS™ methodology.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=353dab4c6bdd" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The research that goes undisclosed …]]></title>
            <link>https://tammylynndavis.medium.com/the-research-that-goes-undisclosed-a2ba2ff90f62?source=rss-bea04f141334------2</link>
            <guid isPermaLink="false">https://medium.com/p/a2ba2ff90f62</guid>
            <category><![CDATA[self-improvement]]></category>
            <category><![CDATA[mental-health]]></category>
            <category><![CDATA[science]]></category>
            <category><![CDATA[stress]]></category>
            <category><![CDATA[healthcare]]></category>
            <dc:creator><![CDATA[Tammy Lynn Davis]]></dc:creator>
            <pubDate>Mon, 10 Aug 2026 22:16:27 GMT</pubDate>
            <atom:updated>2026-08-10T22:16:27.518Z</atom:updated>
            <content:encoded><![CDATA[<h4>… the facts found in the scientific contradictions</h4><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*szuuzwXenCUG2SHQD1DHAw.jpeg" /></figure><p>There is a habit in my field that I have stopped being polite about. When a study finds that an essential oil works, we cite it. When a study finds it doesn’t, we explain it away — wrong dose, wrong delivery, adulterated oil, underpowered sample — or we simply never mention it again. The positive findings become the literature. The nulls become the footnotes nobody reads.</p><p>This is not how you build a science. <strong>It’s how you build a sales funnel with citations.</strong></p><p>So this series is going to do the opposite. Each installment takes a place where the peer-reviewed record genuinely contradicts itself — not fringe studies against solid ones, but competent research pointing in opposite directions — and asks what the contradiction is actually telling us. Because I think it’s telling us something most of aromatherapy, and frankly most of pharmacology, does not want to hear: the population mean is not the unit that matters. People are not interchangeable. Nature doesn’t standardize her subjects, and she certainly didn’t standardize yours.</p><p><strong>Exhibit A: the most studied oil we have</strong></p><p>Start with lavender and anxiety, because if any pairing should have produced a clean answer by now, it’s this one. Lavender is the most clinically studied essential oil in existence. (<em>Yeah, but which lavender oil?</em>) Hundreds of trials. Multiple meta-analyses. A pharmaceutical-grade standardized oral preparation (Silexan) that has gone head-to-head against paroxetine and lorazepam.</p><p><strong>And the record still refuses to resolve.</strong></p><p>A review of inhalation trials found that ten of eleven included studies reported significantly reduced anxiety after lavender inhalation, across nearly a thousand participants. That is about as consistent as this literature gets. The Silexan oral trials show measurable reductions on the Hamilton Anxiety scale against placebo, with the 80 mg dose performing comparably to paroxetine in network meta-analysis.</p><p>Now the other column. A randomized, controlled crossover trial — well designed, properly registered, using high-strength, verified-pure lavender oil applied dermally to people with dementia-related agitation — found <strong>no discernible effect on affect or behavior</strong>. Not a weak effect. No effect, in exactly the kind of rigorous design we keep saying we want more of.</p><blockquote><em>And within the surgical literature, the same intervention that reliably reduces preoperative anxiety shows no difference from control when applied after surgery.</em></blockquote><ul><li>Sit with that last one, because it’s the tell.</li><li>Same oil. Same constituents</li><li>Same route of administration</li><li>Same hospital, in some cases</li></ul><p>The variable that flipped the result was not the lavender. <strong>It was the state of the person receiving it.</strong></p><p><strong>The explanations that explain nothing</strong></p><p>The standard moves here are familiar.</p><ul><li>Blame the dose</li><li>Blame the delivery route</li><li>Blame oil quality — always a crowd-pleaser, because it lets everyone keep their preferred conclusion and gestures vaguely at someone else’s supply chain.</li></ul><p>And to be fair, these variables are real.</p><p>Dermal pharmacokinetics differ from inhalation. <strong>Chemotype matters</strong>. I’ve spent a good portion of my career insisting that it matters.</p><p>But notice what the standard explanations have in common: they all locate the variability in the substance, and none of them locate it in the subject.</p><ul><li>The oil was wrong</li><li>The method was wrong</li><li>The study was wrong</li><li>The person is treated as a constant — a passive assay vessel into which lavender either works or doesn’t.</li></ul><p>The pre-op/post-op split breaks that model. So does the dementia null. A person anticipating surgery is in an aroused, appetitive, threat-scanning state — a nervous system actively searching for information about what happens next. A person recovering from surgery, or a person with dementia-related agitation, is somewhere else entirely:</p><ul><li>Different baseline arousal</li><li>Different receptor availability</li><li>Different capacity for the odor to even register as salient, in some cases a degraded olfactory system outright</li></ul><p>The mechanistic reviews concede, in their careful way, that the pathways behind lavender’s anxiolytic effects remain unclear. I’d put it less carefully:</p><p>We have been measuring an interaction between a chemistry and a nervous system while pretending we were measuring a property of the chemistry alone.</p><p><strong>What the contradiction is telling us</strong></p><p>Here is the reading the field keeps declining to make. When competent studies of the same substance return opposite results, there are three possibilities.</p><ol><li>Some of the studies are bad. Sometimes true, and the least interesting option.</li><li>The substance is inert, and the positives are noise. The Silexan data and the sheer consistency of the inhalation trials make that hard to sustain.</li><li>The effect is real but conditional — contingent on who is receiving it and what state their nervous system is in when they do.</li></ol><p>Option three is not a rescue maneuver. It’s a testable hypothesis with named variables: <strong>baseline autonomic state, olfactory function, prior odor learning, receptor polymorphisms, the metabolic idiosyncrasies that govern what a given body does with linalool </strong>once it arrives. None of these is exotic. Every one of them is known to vary between individuals, and almost none of them is measured, stratified, or even recorded in the trials we keep running. We keep asking whether lavender works. The literature has been answering a different question — for whom, and when — and we keep filing that answer under ‘mixed results’ as though it were an embarrassment instead of the finding.</p><p>To be clear about what I am not claiming: I am not claiming the mechanism is established. The state-dependence reading is a mechanism worth investigating, not a mechanism proven — and the difference between those two things is the entire reason this series exists. What I am claiming is that <strong>the contradictions are data</strong>. A field that gets uniform results across heterogeneous human beings should be more suspicious of itself, not less. <strong>The disagreement in the lavender literature is not the failure of the research program</strong>. It may be the most honest thing the research program has produced.</p><p><strong>Next in the series: </strong>In 2007, the New England Journal of Medicine reported three boys who developed breast tissue after using lavender and tea tree products, and a twenty-year fight broke out over whether the oils were responsible. Buried in the original case report is a detail almost nobody in that fight has centered: one of the boys had a fraternal twin. Same lotion. Same household. No gynecomastia. Everyone argued about the oil. The contrast was ignored.</p><p><em>Tammy L. Davis, MCN, is an instructor at the University of New Mexico and Santa Fe Community College as well as the founder of Aromagenomics and developer of the ANIS™ methodology.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=a2ba2ff90f62" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The ‘house’ you are …]]></title>
            <link>https://tammylynndavis.medium.com/the-house-you-are-dc4c0441b0c2?source=rss-bea04f141334------2</link>
            <guid isPermaLink="false">https://medium.com/p/dc4c0441b0c2</guid>
            <category><![CDATA[addiction]]></category>
            <category><![CDATA[self]]></category>
            <category><![CDATA[homeless]]></category>
            <category><![CDATA[anxiety]]></category>
            <category><![CDATA[mental-health]]></category>
            <dc:creator><![CDATA[Tammy Lynn Davis]]></dc:creator>
            <pubDate>Fri, 03 Jul 2026 12:59:17 GMT</pubDate>
            <atom:updated>2026-07-03T12:59:17.309Z</atom:updated>
            <content:encoded><![CDATA[<h4>… why self-knowing and living in the body are the same homecoming</h4><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*LfCzcq1llA2a1hhEOY83rQ.jpeg" /></figure><p>Heidegger had a word for the anxiety underneath ordinary life: <strong><em>Unheimlichkeit</em></strong></p><p>It gets translated as “the uncanny,” which is a shame, because the literal sense is plainer and more useful. <strong>It means <em>un-home-liness</em> — not being at home</strong>.</p><p>He believed that the familiar going strange is the mood beneath the surface of a life, and that we spend most of our energy papering over it with routine.</p><p>There is a version of this that is not philosophical at all. <strong>It is the experience of not feeling at home in your own body </strong>— of treating the one dwelling you can never leave as the one place you do not quite live. We have a return word for the ache of it, and it is just as literal once you take it apart.</p><p><em>Nostalgia</em> is <em>nostos</em>, homecoming, plus <em>algos</em>, pain. Homesickness.</p><p>The condition of longing for a home you are not in.</p><p>I want to make a case that the home in question is not a metaphor, and that the way back is not the one the culture keeps selling.</p><p>• • •</p><h4>The eviction</h4><p>Start with a fact that is easy to miss because it is so common it reads as weather. Forty years ago, researchers studying women and weight coined a phrase that has not aged out of use: <em>normative discontent</em> (Rodin, Silberstein, &amp; Striegel-Moore, 1984). The finding was that dissatisfaction with one’s own body is so widespread that it is statistically normal, and that feeling fine about your body is the deviation.</p><p>Read that slowly.</p><ul><li>Being unhoused in your own body is the baseline.</li><li>Contentment is the anomaly we treat as suspect.</li></ul><p>How does a whole population end up estranged from the one thing it can never be evicted from? The most durable answer in the literature is <em>self-objectification</em> (Fredrickson &amp; Roberts, 1997). The idea is precise:<strong> a culture that relentlessly presents bodies as things to be looked at trains people to look at their own body from the outside, adopting the observer’s vantage as their primary relationship to their own interior.</strong> You stop living in the body and start monitoring it — from a seat in the audience, watching yourself on stage. The inside-out perspective, the one where the body is where you live <em>from</em>, gets overwritten by an outside-in one, where the body is a thing you <em>have</em> and must manage.</p><p>This is the eviction. Not dramatic, not clinically traumatic for most people — just the slow, culturally sponsored relocation of the self from inside the skin to a monitoring station somewhere above and to the left.</p><blockquote>Renovating a house you have emotionally vacated does not make you live there again.</blockquote><p>• • •</p><h4>The cost</h4><p>This is where the science stops being about attitude and starts being about the nervous system. <strong>Interoception is the name for the body’s sensing of its own internal state </strong>— the reading of signals from the viscera, the ongoing and mostly unconscious report on the condition of the interior. It is, in a real sense, the physiology of being at home in yourself: the felt sense that there is an inside, that it is yours, and that you can feel it.</p><blockquote><strong><em>Disruptions to this system are not specific to any one diagnosis</em></strong><em>.</em></blockquote><p>A neuroimaging meta-analysis pooling <strong>thirty-three</strong> studies (Nord, Lawson, &amp; Dalgleish, 2021) found a convergent disruption in interoceptive processing — localized to the left dorsal mid-insula — across —</p><ul><li>schizophrenia</li><li>depression</li><li>bipolar disorder</li><li>PTSD, anxiety</li><li>eating disorders</li></ul><p>AND</p><ul><li>substance use</li></ul><p>Not the fingerprint of one illness. A shared substrate beneath many. Reviews since have argued that interoception may be a <strong>transdiagnostic marker</strong> of distress more broadly (Nord &amp; Garfinkel, 2022), though the same literature is candid that the crude measures — can you count your own heartbeat — are not reliably impaired in anxiety or depression (Jenkinson, Fotopoulou, Ibañez, &amp; Rossell, 2024). What matters is not raw accuracy but something closer to <em>trust</em>: whether the body registers as a safe interior or a hostile one.</p><p>That distinction is the whole game. In work with survivors of intimate partner violence, the mental-health burden — anxiety, PTSD, depression — was mediated not by how accurately a person could detect internal signals but by bodily dissociation and a diminished sense of the body as their own; those who could perceive the body as safe carried fewer symptoms (reported in a 2025 scoping review in the Psychotherapy and Counselling Journal of Australia). The interpretation is worth sitting with: distracting yourself from bodily sensation is a coping strategy, and over time the distraction itself — the leaving — becomes the liability.</p><p>Which is the homelessness parallel, told in the language of the insula. To be unhoused is not merely to lack a roof. It is to lack a stable interior you can leave and return to — the base that makes venturing out survivable at all. No threshold, no inside, chronic exposure, nowhere to fully rest. Trauma does the same thing to the body: it turns the interior into another exposed street, and the person, sensibly, moves out.</p><p>• • •</p><h4>The sensors</h4><p>Interoception has hardware, and it is worth knowing where it begins, because it is where my own field does its work — and where my field is most tempted to overpromise. The signals that eventually reach the insula start far downstream, as ion channels on visceral and vagal sensory neurons. Among them are the TRP channels: the same molecular sensors that register heat, cold, and the bite of a spice. This is the afferent layer — the raw input, the traffic headed inward before anything has been felt or named.</p><p>It is exactly this layer that pungent botanicals act on.</p><p>Piperine, the alkaloid that makes black pepper hot, is a dual TRPV1/TRPA1 agonist that fires sensory neurons, including those lining the gut (Okumura et al., 2010). Ginger is subtler, because it works in two directions at once: its gingerols and shogaols activate TRPV1 — the warmth — while non-competitively blocking the 5-HT3 receptors on vagal afferents that carry the nausea signal from gut to brainstem (Walstab et al., 2013). It turns one visceral signal up and quiets another in the same gesture. That is not a metaphor for balance. It is balance, transacted at the receptor.</p><p>The aromatic constituents I lean into behave the same way.</p><ul><li>Citral, the bright edge in lemongrass and citrus, touches nearly the entire sensory TRP panel — TRPV1, TRPV3, TRPM8, TRPA1 — exciting the channels and then, unusually, quieting them (Stotz et al., 2008).</li><li>1,8-cineole, the spine of eucalyptus, activates the cooling channel TRPM8 while antagonizing the irritant channel TRPA1 (Takaishi et al., 2012) — which is the pharmacology beneath the felt sense of an open airway, and breath is among the loudest interoceptive signals we own.</li><li>Linalool works nearer the autonomic set point than the pungent channels; in mice its calming effect vanishes in the absence of a sense of smell and is undone by a benzodiazepine blocker, meaning it runs through olfaction and the GABA system rather than by shouting at the viscera (Harada et al., 2018).</li></ul><p>Here is the honest part, and it is the same divide that governs the rest of this essay. All of this works the afferent layer — the bottom-up signal, the input. <strong>It can make the interior <em>audible</em>: turn the volume up on a body someone has stopped listening to, put a sound back in a vacated house</strong>. For a person dissociated from the inside, a signal loud enough to notice can be a foot in the door. But volume is not trust, and salience is not residency. Making the interior audible is not the same as being willing to live there. The molecules can open the door; they cannot walk you through it. And because the literature demands the caveat: this is receptor pharmacology, drawn mostly from cells and animals. No one has yet shown that any of these constituents improves a person’s interoceptive perception. The channels are real. The homecoming is not in the vial.</p><p>• • •</p><h4>The way back is not the one being sold</h4><p>So how does anyone actually move in — not just make the house audible, but live in it? The culture has a ready answer, and it is the wrong one. The offered route home runs through the body’s <em>appearance</em> — fix the house, renovate the exterior, and the feeling of residency will follow. It does not. The evidence points somewhere less flattering to the renovation industry and more interesting.</p><p>Begin with self-knowing. Psychologists have a construct for it: <strong><em>self-concept clarity</em>, </strong>the degree to which your sense of who you are is clearly defined, internally consistent, and stable over time (Campbell, 1990; Campbell et al., 1996). People high in it report higher well-being; people low in it show elevated depression, anxiety, and disordered eating.</p><p>Here is the part that bears directly on the body: without a clear sense of self, people reach outward for one. Lacking an internal definition, they borrow the culture’s — and the culture’s definition of a person, for women especially, is disproportionately a definition of a body (Vartanian, 2009). <strong>Lower self-concept clarity predicts greater internalization of the thin ideal and more appearance-based comparison.</strong> In one of the few studies to test direction over time rather than at a single moment, the arrow ran the way the theory predicts: self-concept clarity at one point prospectively predicted thin-ideal internalization months later, while the reverse did not hold (Vartanian &amp; Nicholls, 2024). <strong>An unclear self goes shopping for a template</strong>. The body is the first thing on the rack.</p><p>Now add self-acceptance. Self-compassion — treating yourself with the ordinary decency you would extend to someone you cared about — is associated with better well-being, and one mechanism has been mapped: it appears to work partly <em>through</em> self-concept clarity (Coutts, Al-Kire, &amp; Weidler, 2023). <strong>Being kind to yourself makes the self easier to see clearly, and a self seen clearly is one you no longer need to outsource</strong>. The endpoint, in the body-image literature, has its own name and its own instrument. It is called <em>body appreciation</em> — not a flattering self-assessment, but something closer to a working relationship: holding a favorable, respectful stance toward the body and, notably, protecting it against the media ideals that would pull the gaze back outside (Tylka &amp; Wood-Barcalow, 2015). It is the operational definition of residency. Of being home.</p><p>• • •</p><h4>Integrity, meaning undivided</h4><p>Here is the thread that runs through all of it. The word we reach for when we mean an intact self is <em>integrity</em>, from <em>integer</em> — undivided, whole. Its opposite is not dishonesty. Its opposite is division. <strong>And not feeling at home in your body is, at the level of mechanism, a division: the self split off from its own interior,</strong> filing reports on itself from the cheap seats. The estrangement the culture calls a body problem is a problem of the undivided self. Self-objectification is the instrument of the split. Self-knowing and self-acceptance are how the halves close — recover.</p><p>This is why the appearance route fails so reliably. It works on the wrong side of the divide. It refines the thing being watched while leaving the watching — the outside-in posture itself — fully intact. You can make the house on the stage very beautiful and still be sitting in the audience. Coming home is not a renovation. It is walking off the stage and back into the body you were narrating.</p><p>Alan Watts had the cleanest version of this, and it undercuts even the framing I have used. He would have said the sense of being a self <em>inside</em> a body — a pilot in a vehicle, a tenant in a dwelling — is itself the homelessness. On that reading you were never exiled by trauma or by the culture; you were exiled by a grammatical error, the small persistent fiction that there is a you <em>and</em> a body it inhabits. <strong>Coming home</strong>, then, is not a journey completed. It <strong>is a division noticed to have been imaginary.</strong> The house you keep trying to get back into is the house you are.</p><p>A caution, because this is the kind of claim that gets oversold. Most of the evidence here is correlational; it shows that self-knowing, self-acceptance, and living in the body travel together, not that one manufactures the others on command. The strongest arrows — the prospective and mediation studies — point in the direction I have described, but they are arrows, not proofs, and the honest version of this essay says <em>associated with</em> where the tidy version would say <em>causes</em>. <strong>That the science is unfinished does not make the pattern less real.</strong> It makes it a place to stand while the rest comes in.</p><p>You do not need the literature to have settled to run the experiment yourself. The next time you catch the outside-in gaze switched on — appraising, measuring, narrating the body from the audience — you can notice that the one doing the watching and the body being watched were never two things. That noticing is not a technique. It is a homecoming. And it is available in the only house you were ever going to get.</p><p><em>Tammy L. Davis, MCN, is a Master Clinical Neuroaromatherapist and the founder of Aromagenomics. Pointless is her newest line — playfully grounded in science, and built on forty years of learning, the hard way, that the body was never the enemy.</em></p><p><strong>References</strong></p><p>Campbell, J. D. (1990). Self-esteem and clarity of the self-concept. <em>Journal of Personality and Social Psychology, 59</em>(3), 538–549. <a href="https://doi.org/10.1037/0022-3514.59.3.538">https://doi.org/10.1037/0022-3514.59.3.538</a></p><p>Campbell, J. D., Trapnell, P. D., Heine, S. J., Katz, I. M., Lavallee, L. F., &amp; Lehman, D. R. (1996). Self-concept clarity: Measurement, personality correlates, and cultural boundaries. <em>Journal of Personality and Social Psychology, 70</em>(1), 141–156. <a href="https://doi.org/10.1037/0022-3514.70.1.141">https://doi.org/10.1037/0022-3514.70.1.141</a></p><p>Coutts, J. J., Al-Kire, R. L., &amp; Weidler, D. J. (2023). I can see (myself) clearly now: Exploring the mediating role of self-concept clarity in the association between self-compassion and indicators of well-being. <em>PLOS ONE, 18</em>(6), e0286992. <a href="https://doi.org/10.1371/journal.pone.0286992">https://doi.org/10.1371/journal.pone.0286992</a></p><p>Fredrickson, B. L., &amp; Roberts, T.-A. (1997). Objectification theory: Toward understanding women’s lived experiences and mental health risks. <em>Psychology of Women Quarterly, 21</em>(2), 173–206. <a href="https://doi.org/10.1111/j.1471-6402.1997.tb00108.x">https://doi.org/10.1111/j.1471-6402.1997.tb00108.x</a></p><p>Harada, H., Kashiwadani, H., Kanmura, Y., &amp; Kuwaki, T. (2018). Linalool odor-induced anxiolytic effects in mice. <em>Frontiers in Behavioral Neuroscience, 12</em>, 241. <a href="https://doi.org/10.3389/fnbeh.2018.00241">https://doi.org/10.3389/fnbeh.2018.00241</a></p><p>Jenkinson, P. M., Fotopoulou, A., Ibañez, A., &amp; Rossell, S. (2024). Interoception in anxiety, depression, and psychosis: A review. <em>eClinicalMedicine, 73</em>, 102673. <a href="https://doi.org/10.1016/j.eclinm.2024.102673">https://doi.org/10.1016/j.eclinm.2024.102673</a></p><p>Nord, C. L., &amp; Garfinkel, S. N. (2022). Interoceptive pathways to understand and treat mental health conditions. <em>Trends in Cognitive Sciences, 26</em>(6), 499–513. <a href="https://doi.org/10.1016/j.tics.2022.03.004">https://doi.org/10.1016/j.tics.2022.03.004</a></p><p>Nord, C. L., Lawson, R. P., &amp; Dalgleish, T. (2021). Disrupted dorsal mid-insula activation during interoception across psychiatric disorders. <em>American Journal of Psychiatry, 178</em>(8), 761–770. <a href="https://doi.org/10.1176/appi.ajp.2020.20091340">https://doi.org/10.1176/appi.ajp.2020.20091340</a></p><p>Okumura, Y., Narukawa, M., Iwasaki, Y., Ishikawa, A., Matsuda, H., Yoshikawa, M., &amp; Watanabe, T. (2010). Activation of TRPV1 and TRPA1 by black pepper components. <em>Bioscience, Biotechnology, and Biochemistry, 74</em>(5), 1068–1072.</p><p>The relationship between interoception and experiences of stress, trauma, and mental illness: A scoping review. (2025). <em>Psychotherapy and Counselling Journal of Australia.</em></p><p>Rodin, J., Silberstein, L., &amp; Striegel-Moore, R. (1984). Women and weight: A normative discontent. <em>Nebraska Symposium on Motivation, 32</em>, 267–307.</p><p>Stotz, S. C., Vriens, J., Martyn, D., Clardy, J., &amp; Clapham, D. E. (2008). Citral sensing by transient receptor potential channels in dorsal root ganglion neurons. <em>PLoS ONE, 3</em>(5), e2082. <a href="https://doi.org/10.1371/journal.pone.0002082">https://doi.org/10.1371/journal.pone.0002082</a></p><p>Takaishi, M., Fujita, F., Uchida, K., Yamamoto, S., Sawada, M., Hatai, C., Shimizu, M., &amp; Tominaga, M. (2012). 1,8-cineole, a TRPM8 agonist, is a novel natural antagonist of human TRPA1. <em>Molecular Pain, 8</em>, 86. <a href="https://doi.org/10.1186/1744-8069-8-86">https://doi.org/10.1186/1744-8069-8-86</a></p><p>Tylka, T. L., &amp; Wood-Barcalow, N. L. (2015). The Body Appreciation Scale-2: Item refinement and psychometric evaluation. <em>Body Image, 12</em>, 53–67. <a href="https://doi.org/10.1016/j.bodyim.2014.09.006">https://doi.org/10.1016/j.bodyim.2014.09.006</a></p><p>Vartanian, L. R. (2009). When the body defines the self: Self-concept clarity, internalization, and body image. <em>Journal of Social and Clinical Psychology, 28</em>(1), 94–126. <a href="https://doi.org/10.1521/jscp.2009.28.1.94">https://doi.org/10.1521/jscp.2009.28.1.94</a></p><p>Vartanian, L. R., &amp; Nicholls, K. (2024). Prospective associations among self-concept clarity, appearance comparisons, and thin-ideal internalization. <em>Self and Identity, 23</em>(7–8), 535–546. <a href="https://doi.org/10.1080/15298868.2024.2416657">https://doi.org/10.1080/15298868.2024.2416657</a></p><p>Walstab, J., Krüger, D., Stark, T., Hofmann, T., Demir, I. E., Ceyhan, G. O., Feistel, B., Schemann, M., &amp; Niesler, B. (2013). Ginger and its pungent constituents non-competitively inhibit activation of human recombinant and native 5-HT3 receptors of enteric neurons. <em>Neurogastroenterology &amp; Motility, 25</em>(5), 439–447. <a href="https://doi.org/10.1111/nmo.12107">https://doi.org/10.1111/nmo.12107</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=dc4c0441b0c2" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Not all adverse reactions are the same …]]></title>
            <link>https://tammylynndavis.medium.com/not-all-adverse-reactions-are-the-same-ceddd3def360?source=rss-bea04f141334------2</link>
            <guid isPermaLink="false">https://medium.com/p/ceddd3def360</guid>
            <category><![CDATA[fragrance]]></category>
            <category><![CDATA[highly-sensitive-people]]></category>
            <category><![CDATA[self-care]]></category>
            <category><![CDATA[self-awareness]]></category>
            <category><![CDATA[environment]]></category>
            <dc:creator><![CDATA[Tammy Lynn Davis]]></dc:creator>
            <pubDate>Thu, 02 Jul 2026 14:40:07 GMT</pubDate>
            <atom:updated>2026-07-02T14:40:07.610Z</atom:updated>
            <content:encoded><![CDATA[<h4>… exploring allergens and environmental sensitivity!</h4><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*FUrvbKrbd9PooQUKstlj1A.jpeg" /></figure><p>Somewhere on the back of a bottle in your bathroom, in type small enough to need good light, there is now a list of names you do not recognize. <strong><em>Linalool. Limonene. Citral. Geraniol</em></strong>. They were always there. The plant made them. What changed is that the law now requires them to be spoken aloud.</p><p>That requirement is worth taking a moment to think about, because it is the quietest of quiet admissions. Y<strong>ou do not have to declare the presence of something inert</strong>. You declare it because it does something — because it meets the body and the body responds. The label is not bureaucratic clutter. It is the industry conceding, in writing, that an essential oil is more than a pleasant smell.</p><p>So the molecules act on us. Good. Now we can have the more interesting conversation, which is about what happens when the answer the body offers is not the one we wanted.</p><p>We have one word for that, and it is the wrong word. <strong>We say <em>allergic</em></strong>.</p><p>The term was coined in 1906 by a physician named Clemens von Pirquet, who built it from two Greek roots — <em>allos</em>, other or altered, and <em>ergon</em>, work or action. Altered reactivity. It was a precise word for a specific immunological event. A century later it has become a popular fallback. Into it we throw the rash, the headache, the burn, the watering eyes, the room someone has to leave. Different events, different causes, different futures — filed under one label as though they were one thing.</p><p>They are not one thing. There are at least six, and they do not call for the same response. Some of them ask you to go slow and build up. One of them asks you to stop entirely. Confusing the two is how a person either lives in needless fear of a bottle of lavender, or pushes through a warning they should have heeded. The cure for both is the same, and it is not reassurance. It is discernment.</p><p>Here, then, is the drawer, emptied out and sorted.</p><h4>One. Irritation.</h4><p>This is the most common, the most misread, and the least serious. Irritation is direct and physical. A constituent meets the skin in too high a concentration, the tissue objects, and you get redness, stinging, sometimes a small angry patch where the oil sat. It is not an immune reaction. It requires no prior exposure, no sensitization, no history. It is simply dose meeting tissue, and it follows the oldest rule in toxicology: enough of anything is too much.</p><p>The tell is that it tracks with concentration. More oil, more occlusion, more time on the skin — more reaction. Dilute it, and the reaction recedes. Most of the people who tell me they are “sensitive to oils” began here, with an undiluted drop on bare skin and a body doing exactly what bodies do.</p><p>Irritation forgives. Skin can acclimate to a stimulus it meets below its threshold; dermatologists call it hardening. This is the first of the reactions that rewards patience over avoidance.</p><h4>Two. The sun one.</h4><p>Some reactions are not the oil’s fault alone. They require an accomplice, and the accomplice is daylight.</p><p>Expressed citrus oils — bergamot most notoriously — carry furocoumarins, molecules that are perfectly quiet in the dark and become reactive under ultraviolet light. Apply the oil, step into the sun, and you can get a burn or a stripe of lasting pigmentation where the oil was. It looks like an allergy. It is a photochemical reaction, a small controlled scorch, and it has nothing to do with the immune system.</p><p>It is also entirely avoidable, which is the point. Respect the hours after application. Keep phototoxic oils off skin that is about to meet the sun, or keep them below the concentrations the trade has worked out precisely to prevent this. A citrus-and-sunlight reaction misfiled as an allergy teaches the wrong lesson and breeds the wrong fear. Named correctly, it simply teaches you to watch the clock.</p><h4>Three. The one that actually is.</h4><p>Now we arrive at the reaction the word was invented for, and here I want to slow down, because this is the one that matters most and is understood least.</p><p>True allergic contact dermatitis is an immune event. It is delayed — it shows up a day or two after contact, not minutes. It spreads beyond where the oil touched. It is confirmed in a clinic by patch testing. And, unlike everything above it on this list, it has a memory. Once the immune system has learned a molecule, it does not unlearn it. Each subsequent exposure tends to come faster and lower than the last.</p><p>The science here is elegant and slightly unsettling. Limonene and linalool — two of the most common names on that label — are weak sensitizers when fresh. But they do not stay fresh. <strong>Exposed to air, they oxidize, and their oxidation products, the hydroperoxides, are potent sensitizers</strong>. The molecule that was nearly harmless in a sealed bottle becomes the molecule that teaches your immune system to react. Lavender oil, studies have shown, has no natural defense against this; left open to the air, it generates strong contact allergens on its own.</p><p>This is not rare. In one consecutive series of more than eight hundred patients, roughly nine percent reacted to oxidized limonene and nearly twelve percent to oxidized linalool, the majority of those reactions judged clinically meaningful. It appears in children, too. These are not fringe findings. They are the reason both molecules were added to Europe’s baseline patch-test panel.</p><p>The lesson is not to fear lavender. The lesson is that the <em>state of the bottle</em> matters as much as the name on it. An oxidized oil is a different chemical proposition than a fresh one. Store them cool and dark. Cap them tightly. Respect a shelf life. Replace the old citrus and the forgotten lavender. You are not just preserving a scent. You are keeping the oil on the right side of its chemistry.</p><p>And if a reaction is delayed, spreading, and worse each time — this is the one to stop. Not slow down. Stop, and get it confirmed. Everything else on this list rewards patience. This one punishes it.</p><h4>Four. The hormone question.</h4><p>This one I will hand to you exactly as the evidence stands, neither inflated nor waved away, because it concerns children and deserves a steady voice.</p><p>In 2007 the <em>New England Journal of Medicine</em> published a report of three young boys who developed breast tissue — prepubertal gynecomastia — after repeated use of products containing lavender or tea tree oil. In each case the condition resolved within months of stopping. The same report found, in the laboratory, that both oils showed weak estrogen-like and anti-androgen-like activity. A later set of experiments extended the finding to several individual constituents.</p><p>That is the case for concern, and it is real. Here is the discipline the subject requires: a systematic review of the human evidence found it genuinely mixed. We have plausibility, we have laboratory activity, we have case reports — and we do not have population-level proof. The honest sentence is “biologically plausible, demonstrated in the lab, not established at scale.”</p><p>So: <strong>natural is not the same as hormonally inert</strong>, and reasonable caution with heavy, chronic use on young children is sensible. Panic is not. Both of those are true at once, and an article that cannot hold both is not telling you the truth.</p><h4>Five. The serious one.</h4><p>The hardest outcomes in the entire literature on essential oils do not come from the skin. They come from the mouth, and almost always they come from children.</p><p>Essential oils are concentrated to a degree that is easy to forget. In a young child, swallowing somewhere between half a teaspoon and a teaspoon of eucalyptus oil can cause serious symptoms; a fatal case has been recorded after a much larger ingestion in an infant. Camphor, wintergreen, clove, tea tree — the same story. Ingested, they can drive the nervous system into agitation and seizures or down into depression and lethargy.</p><p>This is not a reason for fear so much as for respect and a high shelf. Oils are not beverages, not even diluted; a child’s smaller body and immature liver make a dose that an adult would shrug off into something dangerous. The whole category of risk closes almost entirely with two habits: never take oils internally without knowing exactly what you are doing, and keep them where small hands and curious mouths cannot reach. “The dose makes the poison” is five hundred years old. It is still the most useful sentence in the room.</p><h4>Six. The reaction that is not an allergy at all.</h4><p>I have saved this one for last because it is the one most often misnamed, and the one where the misnaming does the most quiet harm.</p><p>There are people who cannot be in the room. A diffuser two doors down brings on a headache, a tightness, a wave of something that feels like the body sounding an alarm. They have usually been told they are allergic. They are usually not.</p><p>What they have is better described as a chemical or sensory intolerance — the clinical literature uses the broader name idiopathic environmental intolerance. The symptoms can mimic allergy and asthma convincingly. But when you look for the fingerprint of an immune reaction, it is not there. These individuals show no exposure-specific immune deviation. The machinery is different.</p><p>The machinery is sensory. Volatile constituents reach the nerve endings of the trigeminal system and activate a family of receptors — the TRP channels, the same ones that register the heat of chili and the cold of mint. The nerve fires, and the body reads it as irritation, as headache, as threat. There is often a second layer woven through it: a learned one, in which the body has come to brace for a scent it has decided is dangerous. The reaction is real. Its origin is neural, not immunological.</p><p>And here is what makes this the hopeful entry on the list. Those same receptors, activated steadily and gently, desensitize. It is the principle behind building a tolerance to capsaicin — the first exposure overwhelms, and with patient repetition the signal quiets. The learned layer answers to the same patience; an alarm that is never followed by harm eventually stops sounding.</p><p><strong>I have watched this happen.</strong> People who could not tolerate aromatics in any form, who began at four drops in ten milliliters of carrier and would have sworn they were allergic, climbing slowly — more oil, more often — until the body stopped treating the scent as an emergency. They did not overcome an allergy, because there was no allergy to overcome. They taught an over-vigilant sensory system that it was safe to stand down. That is a different and, to my mind, a more interesting victory.</p><p>This is where “less is more” earns its keep. For a sensory intolerance, the smallest tolerated dose is not a consolation prize. It is the doorway.</p><h4>The rule that holds it all together</h4><p>If you keep one thing from this, keep the distinction between the reactions that reward patience and the one that does not.</p><p>Irritation, phototoxicity, and sensory intolerance all answer to a careful hand. Start low. Go slow. Build up. The body adapts, the threshold rises, access returns. The hormone question and the poisoning question are about restraint in the vulnerable — keep heavy chronic use off young children, keep oils out of small mouths — and not about titration at all.</p><p>And then there is the one exception that makes the whole framework matter. <strong>True contact allergy — the delayed, spreading, worsening kind — does not adapt.</strong> With that one, going slow does not build tolerance; it builds the allergy. The advice that heals a sensory intolerance is precisely the advice that endangers an allergic person. That is the entire reason the names on the back of the bottle deserve a second look, and the entire reason “allergic” was always too small a word.</p><p>How do you tell them apart? You read the reaction. Fast and dose-dependent and gone when you dilute: irritation. On sun-exposed skin after citrus: light, not allergy. Headache and overwhelm with no rash and no immune signature: a sensory system asking for a smaller dose, not a smaller life. Delayed, spreading, and worse each time: stop, and get it confirmed.</p><h4>Caution, not fear</h4><p>These are not the same posture, though we tend to collapse them.</p><p>Fear is a closed door. It treats every name on the label as a verdict and every reaction as proof that the body cannot be trusted near these things. Caution is an open hand held at a careful distance. It takes the molecule seriously precisely because it respects what the molecule can do — and then it learns the difference between a warning and a sentence.</p><p>To <em>encourage</em>, in the old sense, is to put courage into the heart. That is the whole aim here. Not to send you away from the bottle, and not to wave you carelessly toward it, but to give you enough understanding that you can stand in front of it without flinching and without recklessness. The label finally tells the truth about these oils. The least we can do is read it well enough to answer in kind.</p><p><em>Sources, for those who want them:</em></p><ul><li>Henley DV, Lipson N, Korach KS, Bloch CA. Prepubertal gynecomastia linked to lavender and tea tree oils. <em>N Engl J Med.</em> 2007;356(5):479–485.</li><li>Ramsey JT, et al. Lavender products associated with premature thelarche and prepubertal gynecomastia. <em>J Clin Endocrinol Metab.</em> 2019;104(11):5393–5405.</li><li>Systematic review: lavender and tea tree essential oils and pediatric endocrine disorders. <em>Complement Ther Med.</em> 2020.</li><li>Hagvall L, et al. Lavender oil lacks natural protection against autoxidation, forming strong contact allergens on air exposure. <em>Contact Dermatitis.</em> 2008;59(3):143–150.</li><li>Karlberg AT, Magnusson K, Nilsson U. Air oxidation of d-limonene creates potent allergens. <em>Contact Dermatitis.</em> 1992;26(5):332–340.</li><li>Christensson JB, et al. Linalool — a significant contact sensitizer after air exposure. <em>Contact Dermatitis.</em> 2010;62(1):32–41.</li><li>Consecutive patch-test series, limonene and linalool hydroperoxides (clinical relevance). <em>Contact Dermatitis.</em> 2019 (PMC6587870).</li><li>Flaman Z, et al. Unintentional exposure of young children to camphor and eucalyptus oils. <em>Paediatr Child Health.</em> 2001;6(2):80–83.</li><li>Tibballs J. Clinical effects and management of eucalyptus oil ingestion in infants and young children. <em>Med J Aust.</em> 1995;163(4):177–180.</li><li>The role of flavor and fragrance chemicals in TRPA1 activity. <em>Allergy Asthma Clin Immunol.</em> 2015;11:11.</li><li>Short-term olfactory sensitization, chemical intolerance, and the sensitization/habituation framework. <em>Int J Hyg Environ Health.</em> 2017.</li><li>Posadzki P, Alotaibi A, Ernst E. Adverse effects of aromatherapy: a systematic review. <em>Int J Risk Saf Med.</em> 2012;24(3):147–161.</li></ul><p><em>Tammy L. Davis, MCN, is a Master Clinical Neuroaromatherapist and the founder of Aromagenomics. Her newest line, Pointless, is playfully grounded in science and built on the premise that the body was never the enemy. None of this is medical advice; if something is genuinely wrong, please see someone who can help.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=ceddd3def360" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The practitioner’s guide to phthalate verification in essential oils]]></title>
            <link>https://tammylynndavis.medium.com/the-practitioners-guide-to-phthalate-verification-in-essential-oils-59a0df565a52?source=rss-bea04f141334------2</link>
            <guid isPermaLink="false">https://medium.com/p/59a0df565a52</guid>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[essential-oil]]></category>
            <category><![CDATA[stress]]></category>
            <category><![CDATA[environment]]></category>
            <category><![CDATA[mental-health]]></category>
            <dc:creator><![CDATA[Tammy Lynn Davis]]></dc:creator>
            <pubDate>Wed, 24 Jun 2026 20:12:43 GMT</pubDate>
            <atom:updated>2026-06-24T20:12:43.380Z</atom:updated>
            <content:encoded><![CDATA[<p><em>A step-by-step framework for knowing — with analytical certainty — whether an essential oil is clean. Because the right question is not which brand to trust, but which documentation to demand.</em></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*x5tsagKRgdOmAprG4tBQXg.jpeg" /></figure><p>Most practitioners who take essential oil quality seriously already know to ask for a GC-MS report. What the industry has been slow to clarify is that there are two fundamentally different GC-MS conversations happening simultaneously — and conflating them is where sourcing decisions go wrong.</p><p>The first conversation is about constituent identity: is this lavender actually lavender? Is it adulterated with synthetic linalool, or extended with a cheaper carrier? Standard GC-MS answers these questions well. The second conversation is about contamination: does this oil contain phthalate esters that were never meant to be there? Standard GC-MS, run under a typical constituent analysis protocol, does not reliably answer that question.</p><p>This guide exists to close that gap.</p><p>Understanding the two GC-MS conversations</p><p>Gas Chromatography-Mass Spectrometry works by vaporizing a sample, separating its components through a column, and identifying each compound by its mass spectrum — essentially its molecular fingerprint. The instrument is powerful, but its output is only as useful as the analytical protocol directing it.</p><p><strong>Standard constituent GC-MS</strong></p><p>A standard essential oil GC-MS report scans for the known volatile constituents of a given oil — linalool, linalyl acetate, 1,8-cineole, limonene, and so on. It tells you whether the oil’s chemical fingerprint matches the expected profile for its declared species and chemotype. It will flag obvious adulteration with foreign essential oils or synthetic fragrance compounds that fall within the scan range. It will not, however, specifically target phthalate esters unless the laboratory protocol is designed to do so.</p><p><strong>Phthalate-targeted GC-MS (or GC-MS/MS)</strong></p><p>Phthalate esters are semi-volatile organic compounds — heavier and less volatile than most essential oil constituents. Detecting them accurately requires a protocol that is specifically calibrated for their retention times, scan ranges, and detection thresholds. The gold standard for this analysis is GC-MS/MS (tandem mass spectrometry), which provides a second layer of confirmation that dramatically reduces false positives and increases sensitivity at low concentrations.</p><p>The most rigorous published method for phthalate analysis in oil matrices uses QuEChERS (Quick, Easy, Cheap, Effective, Rugged, and Safe) extraction combined with GC-MS in Selected Ion Monitoring (SIM) mode, achieving detection limits as low as 0.002 mg/kg — well below levels of clinical concern. This is the analytical tier practitioners should be requesting.</p><p><strong>The core distinction to memorize:</strong></p><p>A clean standard GC-MS report confirms what is intentionally in the oil. A phthalate-targeted GC-MS report confirms what should not be there. These are different documents, and one does not substitute for the other.</p><p>The five phthalate esters to screen for</p><p>Not all phthalates carry equal health significance, but the following five are the priority targets for essential oil testing based on their prevalence in contamination studies, their regulatory status, and their endocrine-disrupting potency. Any COA you request should explicitly list results for each of these compounds by name:</p><blockquote><strong>DEHP</strong></blockquote><blockquote>Di(2-ethylhexyl) phthalate — the most studied, highest-potency anti-androgenic phthalate. Regulated in the EU and restricted in children’s products in the US.</blockquote><blockquote><strong>DBP</strong></blockquote><blockquote>Dibutyl phthalate — commonly found in fragrance compounds and nail products; well-documented reproductive toxicant.</blockquote><blockquote><strong>DIBP</strong></blockquote><blockquote>Diisobutyl phthalate — frequently found in Italian citrus oil studies; anti-androgenic in animal models.</blockquote><blockquote><strong>DEP</strong></blockquote><blockquote>Diethyl phthalate — widely used as a fixative in fragrance formulations; one of the most common adulterant-associated phthalates.</blockquote><blockquote><strong>BBP</strong></blockquote><blockquote>Benzyl butyl phthalate — less common but present in some industrial plasticizers; included in EU Annex XIV restricted substances.</blockquote><p>A comprehensive screen may also include dimethyl phthalate (DMP), di-n-octyl phthalate (DnOP), and dipentyl phthalate (DPP). Laboratories conducting rigorous phthalate panels typically screen 11 to 16 phthalate esters simultaneously. Requesting the full panel rather than a targeted five is always the stronger position.</p><p>What to look for in a certificate of analysis</p><p>A COA that genuinely demonstrates phthalate verification will include the following elements. If any of these are absent, the document is incomplete for clinical sourcing purposes.</p><ul><li><strong>Explicit analyte list: </strong>The COA must name each phthalate ester individually by compound name and CAS number, not simply state ‘phthalates: not detected.’ A blanket statement without individual compound identification is analytically meaningless.</li><li><strong>Quantitative results, not just pass/fail: </strong>Results should be reported in ppb (parts per billion) or mg/kg with specific detection limits stated. A COA that reports only ‘ND’ (not detected) without stating the method detection limit (MDL) tells you nothing about how sensitive the test was.</li><li><strong>Analytical method cited: </strong>The COA should reference the specific method used: GC-MS/MS with SIM mode, QuEChERS extraction, EPA Method 8270E, or equivalent. An uncited method cannot be evaluated for adequacy.</li><li><strong>Third-party, ISO/IEC 17025-accredited laboratory: </strong>ISO/IEC 17025 is the international standard for testing laboratory competence. Accreditation means the lab’s methods have been independently validated. Brand-internal testing does not meet this bar.</li><li><strong>Batch-specific lot number: </strong>The COA must correspond to the specific batch you are using, identified by lot or batch number. A COA issued for a product line or a single historical batch does not apply to subsequent production runs.</li><li><strong>Sample receipt and test date: </strong>Dating confirms the test was performed on the actual batch in question, not carried forward from a prior run.</li></ul><p><strong>A note on detection limits:</strong></p><p>If a COA states ‘not detected’ for DEHP but the method detection limit is listed as 5,000 ppb, the test cannot detect contamination below 5,000 ppb — which may still represent a clinically meaningful exposure. Always compare the MDL to the result. The lower the MDL, the more rigorous the screen.</p><p>The questions to ask a supplier — directly</p><p>Most suppliers will not volunteer phthalate-specific testing documentation without being asked. The following questions, asked in writing, create both clarity and accountability. A supplier’s response — or non-response — is itself diagnostic of quality commitment.</p><ol><li><strong>Question one — </strong>“Do you conduct phthalate ester screening separate from your standard GC-MS constituent analysis? If so, which phthalate esters are tested, and by what analytical method?”</li><li><strong>Question two — </strong>“Can you provide a batch-specific COA that includes individual phthalate ester results with stated method detection limits for the lot I am purchasing?”</li><li><strong>Question three — </strong>“Is your phthalate testing conducted by a third-party laboratory with ISO/IEC 17025 accreditation? Can you provide the laboratory’s name and accreditation certificate?”</li><li><strong>Question four — </strong>“What materials are used in your distillation equipment, storage vessels, and transport containers — specifically, are any plastic components in contact with the oil at any point in the production chain?”</li><li><strong>Question five — </strong>“Can you provide information about the water source and growing region for the plant material, and whether soil or water contamination assessments have been conducted for that region?”</li></ol><p>A supplier who can answer questions one through three with documentation is operating at the standard clinical sourcing requires. A supplier who deflects, provides a standard constituent COA in response to a phthalate-specific request, or cannot identify their testing laboratory has not cleared that bar — regardless of brand reputation, price point, or marketing claims.</p><p>Understanding what ‘organic certified’ and ‘GC-MS verified’ actually cover</p><p>Both of these designations are meaningful within their scope — and both have limits that practitioners must understand.</p><p><strong>Organic certification</strong></p><p>USDA Organic or equivalent international certification governs the agricultural production of the plant material: pesticide use, synthetic fertilizer use, and in some cases irrigation source. It does not certify the extraction process, the equipment used, the storage and transport chain, or the final purity of the finished oil. An organic-certified essential oil can legally carry this designation while having been distilled through plastic tubing and stored in phthalate-leaching containers.</p><p><strong>Standard GC-MS verification</strong></p><p>As discussed above, a standard GC-MS report verifies constituent identity and will flag some forms of adulteration. It is a meaningful quality document for what it addresses. It does not certify phthalate-free status unless the protocol specifically targets phthalate esters, because standard constituent analysis is optimized for volatile compounds in the essential oil’s own chemical family — not for the heavier, semi-volatile phthalate diesters.</p><p><strong>The practical implication:</strong></p><p>An oil can be simultaneously organic-certified, GC-MS verified for constituent purity, and phthalate-contaminated. All three of these statements can be true at the same time. This is not a paradox — it reflects the limits of each certification’s scope.</p><p>A minimum verification standard for clinical practice</p><p>For practitioners recommending essential oils in clinical or therapeutic contexts — particularly to populations with hormonal health concerns, elevated allostatic load, or impaired detoxification capacity — the following represents a responsible minimum sourcing standard:</p><ul><li>Batch-specific, third-party COA with individual phthalate ester results (minimum five: DEHP, DBP, DIBP, DEP, BBP), stated method detection limits, and cited analytical method.</li><li>Testing laboratory holds ISO/IEC 17025 accreditation for the specific methods used.</li><li>Supplier can confirm glass or stainless-steel contact throughout distillation, storage, and transport — with no plastic components in contact with the finished oil.</li><li>Constituent GC-MS COA additionally available for species/chemotype verification and adulteration screening.</li><li>Testing conducted at batch level, not product-line level, with lot numbers traceable to the specific units being recommended.</li></ul><p>No sourcing standard eliminates all risk — agricultural uptake from contaminated soil or water is a pathway that even the most rigorous production chain cannot fully control. But requesting this documentation stack shifts the burden of proof appropriately: from the practitioner’s assumption of safety to the supplier’s demonstrated accountability for it.</p><p><strong>The practitioner’s standard:</strong></p><p>The question is not ‘Do I trust this brand?’ Trust is not a clinical standard. The question is: ‘Can this supplier produce batch-specific, third-party, phthalate-targeted analytical data — and will they?’ If the answer is no, the oil has not met the verification threshold clinical practice now requires.</p><p>A final note on biochemical individuality and cumulative exposure</p><p>Even with rigorous sourcing, practitioners working with essential oils in clinical contexts should be aware that phthalate burden is cumulative across exposure sources. Essential oils are one vector among many — cosmetics, food packaging, air, and household materials all contribute to the total body burden.</p><p>This matters clinically because of biochemical individuality in detoxification. Individuals with reduced CYP450 activity, compromised glucuronidation, or SULT polymorphisms will accumulate phthalate metabolites differently than those with robust Phase II pathways. For populations already navigating HPA dysregulation, steroidogenic compromise, or endocrine disruption from other sources, the therapeutic product should not add to the burden it is being used to address.</p><p><em>This is not a reason to abandon essential oils as a therapeutic modality. It is a reason to source them as if the clinical stakes are real — because for some of our patients, they are.</em></p><p><em>Tammy L. Davis, MCN, is a Master Clinical Neuroaromatherapist and founder of Aromagenomics and the essential oil line “Pointless”. She is an educator in public settings, trains licensed healthcare professionals in evidence-based neuroaromatherapy and consults as a private neuroaromatherapy concierge for complex clinical cases. She is the developer of the ANIS™ (Aromatic Neural Integrative System) methodology.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=59a0df565a52" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[How to use genuine essential oils to ‘tune in’, not out …]]></title>
            <link>https://tammylynndavis.medium.com/how-to-use-genuine-essential-oils-to-tune-in-not-out-5308b09b21f5?source=rss-bea04f141334------2</link>
            <guid isPermaLink="false">https://medium.com/p/5308b09b21f5</guid>
            <category><![CDATA[self-improvement]]></category>
            <category><![CDATA[mindfulness]]></category>
            <category><![CDATA[mental-health]]></category>
            <category><![CDATA[adhd]]></category>
            <category><![CDATA[self-awareness]]></category>
            <dc:creator><![CDATA[Tammy Lynn Davis]]></dc:creator>
            <pubDate>Wed, 11 Mar 2026 14:04:15 GMT</pubDate>
            <atom:updated>2026-03-11T14:04:15.661Z</atom:updated>
            <content:encoded><![CDATA[<h4>… what is your body telling you?</h4><figure><img alt="" src="https://cdn-images-1.medium.com/max/989/1*AFBsHygh6YzhibRfc0wOCw.jpeg" /></figure><p>There is a moment most people know well. Something in the body shifts — a sound that won’t quiet, a tension that won’t release, a fatigue that sleep doesn’t touch, a gut that seems to have opinions of its own. And almost immediately, the mind begins its familiar work: What’s wrong with me? How do I fix this? How do I make it stop?</p><p>We have been taught, expertly and repeatedly, to treat the body’s signals as problems to be solved. Symptoms are coded as warnings, malfunctions, or failures. The louder they become, the more urgently we seek to silence them — with medication, distraction, suppression, or the relentless effort of figuring out a solution. We have become, as a culture, remarkably skilled at not listening.</p><p>What if that entire orientation is backwards?</p><h4>The Body as Communicator</h4><p>The nervous system is, at its core, a sophisticated information-gathering and signaling system. From the moment you wake, your body is doing something neuroscience calls <strong>interoception</strong> — the continuous sensing, interpreting, and integrating of signals from within.</p><ul><li>Heart rate</li><li>Gut tension</li><li>The subtle shift in breath</li><li>The way your chest opens or closes in response to an idea</li></ul><p>These are not random noise. They are data.</p><p>Damasio’s somatic marker hypothesis established decades ago that <strong>the body registers meaningful information — including</strong> <strong>signals about threat, safety, desire, and aversion</strong> — before the conscious mind catches up. The “gut feeling” is not a metaphor. It is physiology. Your body is voting on your experience in real time, and it was doing so long before language gave it words.</p><p>Interoceptive awareness — the ability to notice and work with these inner signals — i<strong>s now linked in peer-reviewed research to better emotional regulation</strong>, more accurate decision-making, greater resilience, and improved outcomes across virtually every health domain. The body is not just a vehicle for the brain’s agenda. It is a co-author of every experience you have.</p><p>And yet. When the body raises its voice — through pain, through fatigue, through persistent and inconvenient symptoms — our first instinct remains the same: fix it/make it stop.</p><h4>Tinnitus: A Case Study in the Unsilenceable</h4><p>Consider tinnitus. Somewhere between 10 and 15 percent of the global population lives with some form of it — a ringing, humming, or high-pitched tone that medicine largely classifies as untreatable. “Learn to live with it” is among the most common things a person with tinnitus is told by their provider.</p><p>What neuroscience now reveals is far more interesting than that shrug suggests. Tinnitus isn’t truly a hearing problem. It’s considered to be ‘nerve pain’. However, a broader perpective suggests <strong>it could be a window into how the brain processes and filters internal signals</strong> — and what happens when that filtering system becomes overwhelmed.</p><p>Rauschecker’s limbic gating model, published in <em>Neuron</em>, identifies the ventromedial prefrontal cortex and nucleus accumbens as the brain’s “noise cancellation” system — the structure that evaluates whether a signal needs to reach conscious awareness or be quietly filtered out. <strong>When this frontostriatal system becomes compromised</strong> — through chronic stress, GABA depletion, serotonin dysregulation, inflammation, or unprocessed emotional load — <strong>signals that should be gated leak through</strong>. The tinnitus signal, rather than being filtered as irrelevant, is amplified as meaningful.</p><p>In other words, tinnitus is not just a sound. It is evidence of a system under strain — <strong>a nervous system that has lost its capacity to distinguish signal from noise</strong> because it has been operating in overwhelm for so long that everything feels equally urgent.</p><p>This is not a doomsday message. It is a doorway.</p><p>Because the same frontostriatal system that fails in tinnitus is the system that governs emotional regulation, attentional filtering, and the evaluation of sensory experience across every aspect of life. And the same neurochemical scaffolding — GABA, serotonin, dopamine, endocannabinoids — that either supports or undermines that system is, remarkably, accessible.</p><h4>The Addiction Mirror — and Why It Matters for All of Us</h4><p>Here is where the conversation widens beyond tinnitus, and beyond any single diagnosis.</p><p>The person who reaches for a substance to quiet an internal signal they cannot tolerate and the person who white-knuckles through years of chronic symptoms while desperately seeking a cure are engaged in the same neurobiological ‘storm’. <strong>Both are responding to an intolerable inner experience by moving away from it</strong> — outward, urgently, in search of relief that arrives from somewhere outside the body.</p><p>The brain’s appetitive state — what neuroscience has now reframed as the dopaminergic mesolimbic seeking system, a.k.a. reward pathway — <strong>is not pathology. </strong>It is survival.</p><ul><li>Pain activates it</li><li>Disconnection activates it</li><li>The body’s unheard signals, building in volume over time, activate it</li></ul><p>As Michael Beckwith observed with striking neurobiological accuracy: pain pushes until the vision pulls.</p><p>The tragedy is not that people seek relief. It is that relief — <strong>real relief — requires the very thing the pain has made feel impossible</strong>:</p><blockquote><em>turning inward rather than outward</em></blockquote><ul><li>Attending to the signal rather than suppressing it</li><li>Meeting the body with curiosity rather than alarm</li></ul><p>Self-acceptance, in this framework, is not a soft concept. It is the neurochemical pivot point. It is the moment the threat response quiets enough for the system to receive its own information — and begin working with it rather than against it.</p><h4>Why Genuine Essential Oils — and Why Now</h4><p>This is where the practical and the profound intersect.</p><p>The olfactory system is the only sensory system with a direct, unmediated pathway to the limbic brain — the very structures governing emotional memory, threat evaluation, and the frontostriatal gating system implicated in tinnitus, addiction, chronic stress, and interoceptive disconnection. An aromatic molecule inhaled does not take a detour through the thalamus for cognitive sorting. It arrives. It lands in the amygdala, the hippocampus, the insula — precisely where the body’s signal-processing happens.</p><p>But this only holds true for genuine essential oils. Synthetic fragrance molecules activate olfactory receptors without the biochemical complexity that plant-derived constituents carry. The brain recognizes the difference at a receptor level. Genuine essential oils contain dozens to hundreds of bioactive constituents — each with documented interactions with the nervous system.</p><ul><li>Linalool (found in such oils as sweet basil, most lavender oils, rosewood, clary sage, coriander seed, plus) modulates GABA-A receptors, supporting the inhibitory tone that the overwhelmed nervous system so desperately needs.</li><li>Beta-caryophyllene (found in black pepper, helichrysum, copaiba, ylang ylang, clove and more) acts as a CB2 agonist, reducing neuroinflammation and downregulating the overactive threat cascade.</li><li>Alpha- and beta-pinene (found in most oils, although not all) support gray matter integrity and attentional clarity.</li></ul><p>These are not aromatherapy claims. These are documented molecular interactions.</p><p>What makes the ANIS™ framework distinct is this: <strong>the goal is not to select an oil for a symptom.</strong> It is to use aromatic attunement as a practice for returning to the sensing state — the parasympathetic, interoceptively alive state in which the body’s intelligence becomes accessible.</p><p><strong>The oil is not the intervention.</strong> Your returning attention is.</p><h4>A Practice, Not a Protocol</h4><p>Here is what this looks like in daily life, regardless of what you are living with.</p><p>Choose a genuine single-origin essential oil — <strong>one that genuinely appeals to you today, not one that worked last week or that an article said you should use</strong>.</p><blockquote><em>Your attraction to a particular aroma on a particular day is itself interoceptive data.</em></blockquote><p>Before applying or inhaling, pause. Take a breath and notice what is present in the body right now — not what you think you should feel, not what you are afraid of, but what is actually here. A heaviness in the chest. A tightness in the jaw. A low-grade hum of restlessness. A quiet.</p><p>Introduce the aroma. Breathe slowly. And now — notice again. Not whether it “worked.” Not whether you feel better. Notice what shifted, however slightly. That noticing is the practice. That is interoception in action.</p><p>Over time, <strong>this practice rewires the relationship between the inner signal and response</strong>.</p><ul><li>The symptom that once triggered fear becomes a prompt for inquiry.</li><li>The sensation you once fled becomes information you can work with.</li><li>The body stops being something that happens to you and begins to be something you are in conversation with.</li></ul><p>This is attunement to wellness. Not the absence of symptoms, but the capacity to receive them as meaningful — and therefore navigable.</p><h4>An Invitation</h4><p>Whatever you are living with — tinnitus, chronic pain, anxiety, fatigue, addiction in recovery, grief, the low-frequency hum of a life lived slightly outside yourself — <strong>your system is not broken</strong>. It is not failing you.</p><blockquote><strong><em>It is speaking to you in the only language it has: sensation.</em></strong></blockquote><p>The question is never <em>how do I silence this?</em> The question is, <em>what is this asking me to pay attention to?</em></p><p>Genuine essential oils, used with intention and biochemical intelligence, offer one of the most accessible, direct, and scientifically grounded tools available for answering that question. Not because they fix anything. Because they help you come home to yourself long enough to hear what has been waiting to be heard.</p><p>That is not a small thing. That is, in fact, everything.</p><p><em>Tammy L. Davis, MCN, is a Master Clinical Neuroaromatherapist, founder of Aromagenomics™️, and developer of the ANIS™ (Aromatic Neural Integration System). She trains licensed healthcare professionals, including nurse practitioners, pharmacists, and addiction treatment specialists, in evidence-based neuroaromatherapy. She serves as a peer reviewer for pharmacology journals and speaks internationally on addiction neuroscience and the science of olfaction, and is the author of</em> <em>The Scent of Enough</em> <em>and currently writing her book series, with the first one available now</em>: <a href="https://www.amazon.com/Same-Plant-Different-Medicine-Constituent-Based-ebook/dp/B0GR6B4P5H/ref=sr_1_1?crid=37T9KFVG6HRVE&amp;dib=eyJ2IjoiMSJ9.JdEGilSio79rUY8keQauOA.SzRvj3Ug_zJ8uYls28g1pYCxR2SHSnY771Pz8377KlU&amp;dib_tag=se&amp;keywords=A+Constituent-Based+Guide+to+Essential+Oils%3A+Species%2C+Chemotypes%2C+and+Biochemical+Individuality&amp;nsdOptOutParam=true&amp;qid=1773086883&amp;sprefix=a+constituent-based+guide+to+essential+oils+species%2C+chemotypes%2C+and+biochemical+individuality%2Caps%2C182&amp;sr=8-1"><strong><em>A Constituent-Based Guide to Essential Oils: Species, Chemotypes, and Biochemical Individuality</em></strong></a></p><blockquote><em>I currently have 3 spots left for private consultations. </em><a href="https://calendly.com/tammy-aromagenomics/30min"><strong><em>Book your discovery call today to see if this work is a fit for you!</em></strong></a></blockquote><p><a href="https://aromagenomics.com/"><strong>Aromagenomics.com</strong></a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=5308b09b21f5" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The Oil That Changes the Conversation]]></title>
            <link>https://tammylynndavis.medium.com/the-oil-that-changes-the-conversation-b61453089583?source=rss-bea04f141334------2</link>
            <guid isPermaLink="false">https://medium.com/p/b61453089583</guid>
            <category><![CDATA[emotional-intelligence]]></category>
            <category><![CDATA[self-care]]></category>
            <category><![CDATA[microbiome]]></category>
            <category><![CDATA[mental-health]]></category>
            <category><![CDATA[stress]]></category>
            <dc:creator><![CDATA[Tammy Lynn Davis]]></dc:creator>
            <pubDate>Tue, 03 Mar 2026 00:08:12 GMT</pubDate>
            <atom:updated>2026-03-03T00:08:12.276Z</atom:updated>
            <content:encoded><![CDATA[<h4>…what mānuka essential oil is quietly doing inside your immune system — and why almost no one is talking about it correctly … if they are</h4><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*-pdZ-gDuhXr2RR3Xd6f9cg.jpeg" /></figure><p>Perhaps you’ve heard of mānuka. Maybe you’ve used the honey for a sore throat, or even seen the essential oil marketed alongside tea tree as a “<em>powerful natural antimicrobial</em>.” That’s not wrong — but it’s a bit like describing a symphony as “loud.” Technically accurate. Completely missing the point.</p><p>What’s happening inside mānuka essential oil at the synergistic level — particularly in the context of your immune system and your gut — is one of the more genuinely <strong>fascinating stories in aromatic medicine</strong>. And most of it isn’t making it into mainstream wellness conversations.</p><p>Let’s change that.</p><h4>Your Gut Is Running Your Immune System</h4><p>Here’s something that surprises most people: r<strong>oughly 70 to 80 percent of your immune tissue lives in and around your digestive tract</strong>. The gut isn’t just processing food — it’s actively sampling everything that passes through, <strong>communicating with your microbiome</strong>, and making constant decisions about what’s a friend and what’s a threat. When that system is calm and balanced, you tend to feel well. When it’s chronically activated — often silently, without obvious digestive symptoms — the downstream effects can show up anywhere: skin, mood, hormones, brain function, joint inflammation.</p><p>This is the terrain that mānuka essential oil, when properly understood, becomes genuinely interesting.</p><h4>A Chemistry Like Nothing Else</h4><p>What sets mānuka apart from every other essential oil in your collection is a group of compounds called β-triketones — specifically leptospermone, flavesone, and isoleptospermone. These are not terpenes. They’re not the esters or phenols you find in lavender or oregano. They are a rare class of molecules found almost exclusively in certain plants of the Myrtaceae family, and they work through an entirely different mechanism than any other antimicrobial essential oil on the market.</p><p>While most antimicrobial oils work by disrupting microbial cell membranes — think of it as puncturing a balloon — the <strong>β-triketones appear to act as enzyme inhibitors, interfering with bacterial metabolism at a deeper level</strong>. This creates a highly selective antimicrobial profile: exceptional potency against gram-positive bacteria (think Staphylococcus aureus, Streptococcus species, the bacteria most commonly associated with skin infections, post-antibiotic gut imbalances, and certain patterns of small intestinal dysbiosis), with comparatively less disruption of gram-negative bacterial populations that include many of the beneficial species in a healthy microbiome.</p><blockquote>Selective antimicrobial activity isn’t a limitation. In the context of gut health, it may be exactly the point.</blockquote><p>But here’s the piece that rarely makes it into the marketing materials.</p><h4>The Immune Finding Most People Have Never Heard Of</h4><p>A 2016 study published in the <em>Journal of Microbiology, Immunology and Infection</em> did something most essential oil research doesn’t bother to do: <strong>it tested mānuka oil directly on human immune cells</strong>. Specifically, on macrophages — the frontline immune cells that patrol the gut wall, sample the environment, and decide when to sound the inflammatory alarm.</p><p>The researchers stimulated those macrophages with lipopolysaccharide (LPS) — the endotoxin released by gram-negative bacteria, the primary molecular trigger for the kind of chronic, low-grade intestinal inflammation associated with dysbiosis and increased gut permeability. Then they introduced mānuka essential oil.</p><p>What they found was specific and striking: a significant reduction in TNF-α, one of the body’s most powerful pro-inflammatory signaling molecules and a central driver of intestinal inflammatory cascades. And critically — immune function itself was not suppressed. Another key immune marker, IL-4, was left intact.</p><p>This distinction matters enormously. <strong>The oil wasn’t <em>blunting</em> the immune response. It was selectively interrupting a specific inflammatory pathway</strong> while leaving the body’s repair and defense capacity untouched.</p><blockquote><strong><em>That’s a very different thing from simply “being anti-inflammatory.”</em></strong></blockquote><h4>And Then There’s the Gut Itself</h4><p>Separate from the immune cell research, a 1998 study found that mānuka essential oil produces a spasmolytic effect on intestinal smooth muscle — specifically the small intestine. <strong>It relaxes involuntary muscle contractions</strong>. For anyone who has experienced the cramping, spasms, and visceral discomfort associated with IBS or functional bowel conditions, that’s not a minor footnote.</p><p>And a small human clinical trial from 2009 — the only one of its kind — found that patients who gargled a blend containing mānuka essential oil during radiation therapy experienced significantly delayed onset of mucosal inflammation, less pain, and notably less weight loss than control groups. The mucosal tissue of the mouth and throat shares the same immunological architecture as the gut lining. The mechanisms that protected one protected the other.</p><p>None of this is in the typical mānuka product description.</p><h4>The Part Where It Gets Complicated</h4><p>Here’s where genuine expertise matters — and where most wellness content falls short.</p><p>Not all mānuka essential oil is the same. <strong>The β-triketone compounds responsible for the mechanisms above are found in high concentrations only in the East Cape region of New Zealand’s North Island</strong>. Oils from other regions, or without verified constituent analysis, may contain virtually no triketones. They carry the same name. They are not the same medicine.</p><blockquote><em>And mānuka essential oil is </em><strong><em>not</em></strong><em> mānuka honey.</em></blockquote><p>The compounds that drive the honey’s research — methylglyoxal, Lepteridine — are not present in the steam-distilled oil. These are different preparations with different chemistry and different evidence bases. Conflating them is one of the most common errors in wellness content about mānuka, and it quietly misleads people who deserve better information.</p><blockquote>The name on the bottle tells you almost nothing. The constituent analysis tells you everything.</blockquote><h4>Why This Matters Beyond One Oil</h4><p>Mānuka’s story is compelling on its own — but it’s also a perfect illustration of a larger principle that transforms how you relate to every essential oil you use.</p><p><strong>When you understand that oils are not interchangeable based on name</strong>, that constituents drive mechanisms and mechanisms drive outcomes, that your individual biochemistry determines your response — <strong>you stop using essential oils as generic remedies and start using them as the precise, plant-derived chemistry they actually are</strong>. You ask different questions. You get different results.</p><p>That shift — from generic to constituent-specific, from population-level to biochemically individualized — is what the seven-book series</p><p><em>A Constituent-Based Guide to Essential Oils: Species, Chemotypes, and Biochemical Individuality</em> is built around. Every chapter examines a specific oil’s chemistry with the same depth you’ve just encountered here for mānuka (which is coming in book 2) — the mechanisms, the evidence, the variables that determine whether and how a given oil serves a given person.</p><p>Because that’s what you deserve when you reach for a bottle. Not a label claim. Not a vague wellness promise. The actual science — clearly explained, honestly presented, and genuinely useful.</p><blockquote>A Constituent-Based Guide to Essential Oils: Species, Chemotypes, and Biochemical Individuality is a seven-book series by Tammy L. Davis. Book 1 is <a href="https://www.paypal.com/ncp/payment/8FPVBHE6CM8AG"><strong>available here</strong></a>. Written for wellness professionals, nurses, nurse practitioners, and any curious mind ready to move beyond generic aromatherapy into the science of how aromatic plant chemistry actually works in the human body.</blockquote><p><em>© Tammy L. Davis | Aromagenomics</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=b61453089583" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[How Gut Dysbiosis, Ectopic Olfactory Receptors, & Environmental Stress Drive Neuroinflammation…]]></title>
            <link>https://tammylynndavis.medium.com/how-gut-dysbiosis-ectopic-olfactory-receptors-environmental-stress-drive-neuroinflammation-d334e6d42787?source=rss-bea04f141334------2</link>
            <guid isPermaLink="false">https://medium.com/p/d334e6d42787</guid>
            <category><![CDATA[anxiety]]></category>
            <category><![CDATA[mental-health]]></category>
            <category><![CDATA[holistic-health]]></category>
            <category><![CDATA[wellness]]></category>
            <category><![CDATA[stress]]></category>
            <dc:creator><![CDATA[Tammy Lynn Davis]]></dc:creator>
            <pubDate>Mon, 23 Feb 2026 21:34:11 GMT</pubDate>
            <atom:updated>2026-02-23T21:34:11.288Z</atom:updated>
            <content:encoded><![CDATA[<h4>…When Wholesome Becomes Harmful</h4><blockquote><em>If you are experiencing </em><strong><em>ANY</em></strong><em> symptoms or emotional/physical discomforts at all, please read this for yourself.</em></blockquote><blockquote><em>If you are a parent, expecting a child, or specialize in prenatal care…you not only want to read this, but another article I wrote specifically about how maternal dysbiosis affects the unborn. </em><a href="https://tammyld8.substack.com/p/how-maternal-gut-dysbiosis-programs?r=qvhl9"><strong>Click here for that article</strong><em>.</em></a></blockquote><h4>The Paradox of the Conscientious Eater</h4><p>Among the most clinically frustrating presentations in functional and integrative medicine is the patient who has done everything right. They have eliminated processed foods, embraced whole plant foods, committed to fermented vegetables and prebiotic-rich legumes — and yet they feel worse. Mood is flat. Anxiety persists or intensifies. Cognitive sharpness dims precisely when their diet is cleanest.</p><p>This is not a failure of patient compliance. It is, the emerging literature now makes clear, a failure of clinical framing. The food is not the problem. The microbial ecosystem through which that food is processed is the problem. And that ecosystem — when disrupted — can transform even the most nutritionally exemplary meal into a substrate for inflammatory neurochemistry.</p><p>This article assembles the mechanisms behind that transformation, drawing on peer-reviewed research in clinical gastroenterology, neuroimmunology, chemosensory biology, and psychoneuroimmunology. The goal is not a comprehensive literature review but a clinically navigable map of a cascade that begins in the gut, moves through the immune system, and culminates in measurable neurohormonal dysregulation — and that can be entered from multiple environmental points that have nothing to do with diet.</p><blockquote>“The gut in a state of dysbiosis is not merely an unhealthy gut — it is a neuroinflammatory organ, remodeling mood chemistry through pathways that bypass consciousness entirely.”</blockquote><h4>The Microbiome-Gut-Brain Axis: Architecture of a Two-Way Conversation</h4><p>The gut-brain axis is not a metaphor. It is a measurable, multi-channel communication network linking the gastrointestinal epithelium, the enteric nervous system, the vagus nerve, the immune system, and the central nervous system in continuous bidirectional dialogue. Disruption at any point in this network propagates consequences in both directions.</p><p>The gut microbiome — the estimated 100 trillion bacteria, fungi, viruses, and archaea inhabiting the gastrointestinal tract — participates in this dialogue not as passive passengers but as active molecular agents. They produce and modulate neurotransmitters, regulate immune tone, generate the short-chain fatty acids that serve as signaling molecules throughout the body, and metabolize dietary components in ways that are either neuroprotective or neurotoxic depending on microbial community composition.</p><h4>What Dysbiosis Does</h4><p>Dysbiosis — imbalance in the gut microbial community characterized by depletion of beneficial species, overgrowth of pathogenic or commensal species in inappropriate locations, and reduced diversity — disrupts this system at multiple levels simultaneously. It compromises the integrity of the gut epithelial barrier, reduces short-chain fatty acid production, alters enteroendocrine signaling, and promotes translocation of bacterial endotoxins into systemic circulation.</p><p>What is less well appreciated clinically is that dysbiosis also fundamentally reshapes neurochemistry — not only through the gut-brain axis as classically described, but through a specific enzymatic pathway that represents the dominant fate of dietary tryptophan in the human body.</p><blockquote>Kris-Etherton PM, et al. Stress, Depression, Diet, and the Gut Microbiota. Progress in Cardiovascular Diseases. 2020;65:88–95. doi:10.1016/j.pcad.2020.04.001 | PMC7213601</blockquote><h4>When Healthy Foods Become Inflammatory: FODMAPs, Histamine, and the Dysbiotic State</h4><p>Understanding why clean eating can worsen mood in a dysbiotic gut requires understanding two phenomena that occur when fermentable, nutrient-dense foods meet an overgrown or imbalanced microbial community.</p><p><strong>The FODMAP Paradox</strong></p><p>Fermentable oligosaccharides, disaccharides, monosaccharides, and polyols — collectively FODMAPs — are found in abundance in some of the most nutritionally celebrated foods: garlic, onions, legumes, apples, asparagus, and cruciferous vegetables. These compounds are prebiotics; in a healthy microbiome they selectively feed beneficial bacteria, driving the production of butyrate and other short-chain fatty acids that are anti-inflammatory, gut-protective, and neurochemically supportive.</p><p>In a dysbiotic gut — and particularly in SIBO, where bacteria have overpopulated the small intestine where they do not belong — these same fermentable carbohydrates instead fuel pathogenic or mislocated bacterial communities. The result is rapid fermentation, gas production, intestinal distension, and, importantly, the production of metabolites that drive inflammatory signaling rather than soothing it. The prebiotic has become a substrate for the very overgrowth it would otherwise prevent.</p><p>This is why 86% of IBS patients experience symptom improvement on a low-FODMAP diet. The improvement is not because the foods were inherently harmful — it is because the microbiome was not in a state to process them appropriately.</p><p><strong>The Histamine-DAO-Dysbiosis Loop</strong></p><p>A second mechanism operates through histamine metabolism. Gut dysbiosis promotes overgrowth of histamine-secreting bacteria — including Proteus, Raoultella, and related species — while simultaneously depleting the bacteria that degrade histamine. This microbial shift reduces production of diamine oxidase (DAO), the primary enzyme responsible for metabolizing dietary histamine in the intestinal mucosa.</p><p>The patient now faces a biochemical trap: high-histamine foods that would be processed without issue in a healthy gut — fermented foods, aged cheeses, spinach, avocado, tomatoes — arrive in a gut that cannot adequately break them down. <strong>Histamine accumulates, crosses the gut barrier at elevated concentrations, and exerts systemic effects including HPA axis activation, modulation of dopamine and serotonin receptors, and mast cell degranulation</strong> — all of which compound neuroinflammation and mood dysregulation.</p><p>The clinical irony is acute: <strong>a patient instructed to add fermented foods to support their microbiome may be administering exactly the histamine load their dysbiotic, DAO-depleted gut cannot handle</strong>, producing worsened anxiety and mood instability as the measurable result.</p><blockquote>Dietary Treatment of Histamine Intolerance Reduces Histamine-Secreting Bacteria. Frontiers in Nutrition. 2022. doi:10.3389/fnut.2022.1018463 | PMC9633985</blockquote><h4>The Kynurenine Pathway: How Inflammation Hijacks Tryptophan</h4><p>Serotonin’s central role in mood regulation is among the most widely communicated concepts in popular neuroscience. What is communicated with far less frequency — and far less accuracy — is what actually happens to the amino acid tryptophan once it enters the body.</p><p>Ninety to ninety-five percent of dietary tryptophan is not converted to serotonin. It is metabolized through the kynurenine pathway, a metabolic cascade whose products range from neuroprotective to profoundly neurotoxic depending on the inflammatory environment in which it operates.</p><p><strong>The Pathway Under Homeostatic Conditions</strong></p><p>Under normal, low-inflammation conditions, the kynurenine pathway produces a mixture of metabolites that includes kynurenic acid (KYNA) — an NMDA receptor antagonist with neuroprotective properties — along with downstream metabolites that ultimately contribute to NAD+ synthesis. The balance between the neurotoxic and neuroprotective branches of the pathway is maintained by the relative activity of two key enzymes: kynurenine aminotransferase (KAT), which produces neuroprotective KYNA, and kynurenine monooxygenase (KMO), which produces the precursors to neurotoxic quinolinic acid.</p><p><strong>What Inflammation Does to the Pathway</strong></p><p>When pro-inflammatory cytokines — particularly interleukin-6 (IL-6), interferon-gamma (IFN-γ), and tumor necrosis factor-alpha (TNF-α) — are elevated, as they are in states of gut dysbiosis and leaky gut, the enzyme indoleamine 2,3-dioxygenase (IDO) is strongly induced. IDO activation in inflammatory states massively accelerates tryptophan catabolism through the kynurenine pathway.</p><p>The consequences are twofold and compound one another.</p><ol><li>Tryptophan is depleted from circulation, leaving less available to cross the blood-brain barrier for central serotonin synthesis.</li><li>The inflammatory environment simultaneously activates KMO, shifting the balance of kynurenine metabolites away from neuroprotective KYNA and toward the neurotoxic quinolinic acid (QUIN) — a potent NMDA receptor agonist that, at elevated concentrations, drives glutamatergic excitotoxicity, oxidative stress, and neuronal dysfunction.</li></ol><blockquote>“The patient experiencing emotional flatness, anhedonia, or mood instability after eating may not be imagining the connection. Their gut inflammation has mathematically reduced the substrate available for serotonin synthesis while simultaneously generating the very compounds that damage neurons.”</blockquote><p><strong>SIBO Specifically: The Clinical Evidence</strong></p><p>The most clinically direct evidence for this mechanism in a SIBO-specific population comes from the research group of Chojnacki and colleagues at the Medical University of Lodz, Poland — a series of three studies that together constitute the strongest available clinical anchor for this article’s central argument.</p><p>In the first study (2022), 40 patients with diarrhea-predominant SIBO were compared with 40 healthy controls. Urinary tryptophan metabolites were measured by liquid chromatography-tandem mass spectrometry. SIBO patients showed significantly elevated kynurenine and quinolinic acid compared to controls, a higher KYN/TRP ratio indicating tryptophan shunting through the inflammatory pathway, and a lower KYNA/KYN ratio indicating a shift toward the neurotoxic branch. Critically, depression scores (Hamilton Depression Rating Scale) correlated significantly with intestinal inflammatory markers including fecal calprotectin and intraepithelial lymphocyte count.</p><p>In the follow-up treatment study (2022), rifaximin treatment in both diarrhea-predominant and constipation-predominant SIBO groups produced normalization of kynurenine pathway metabolite profiles — and this normalization correlated directly with improvement in both anxiety and depression scores. The microbiome had been perturbing the neurochemistry; its restoration restored mood.</p><p>In the third study (2023), the same methodology was applied to IBS patients without SIBO, revealing that constipation-predominant IBS was specifically associated with elevated kynurenines and a significant correlation between quinolinic acid levels and Hamilton Depression Rating scores — confirming that the kynurenine-mood connection is not limited to SIBO but applies across the spectrum of gut dysbiosis.</p><blockquote>Chojnacki C, et al. Altered Tryptophan Metabolism on the Kynurenine Pathway in Depressive Patients with SIBO. Nutrients. 2022;14(15):3217. doi:10.3390/nu14153217 | PMC9370164</blockquote><blockquote>Chojnacki C, et al. Antimicrobial Treatment Improves Tryptophan Metabolism and Mood in SIBO Patients. Nutr Metab (Lond). 2022;19:66. doi:10.1186/s12986–022–00700–5 | PMC9513933</blockquote><blockquote>Chojnacki C, et al. Changes in Tryptophan Metabolism on Serotonin and Kynurenine Pathways in IBS Patients. Nutrients. 2023;15(5):1262. doi:10.3390/nu15051262 | PMC10005076</blockquote><h4>LPS, TLR4, and IDO: The Leaky Gut–Depression Cascade</h4><p>The mechanism connecting gut dysbiosis to IDO activation and mood disruption has a precise molecular pathway, and its central intermediary is <strong>lipopolysaccharide (LPS)</strong> — the endotoxin constituent of the outer membrane of Gram-negative bacteria.</p><p>Under conditions of dysbiosis, the tight junction proteins that maintain intestinal epithelial barrier integrity — claudin, occludin, ZO-1, and ZO-2 — are downregulated. LPS translocates from the intestinal lumen into systemic circulation, a condition termed metabolic endotoxemia. Even at sub-septic concentrations, circulating LPS binds to Toll-like receptor 4 (TLR4) on peripheral immune cells, macrophages, and microglia, initiating a pro-inflammatory cytokine cascade: TNF-α, IL-1β, and IL-6 are released in significant quantities.</p><blockquote><em>Did someone mention … autoimmune disorders???</em></blockquote><p>These cytokines do not remain peripherally contained. They cross the blood-brain barrier, activate central microglia, and — critically — induce IDO in brain tissue, completing the loop from gut barrier failure to central tryptophan shunting and serotonin depletion. This is the neurochemical basis for the clinical observation that gut inflammation produces depression-like states.</p><p>The foundational mechanistic proof for this cascade comes from O’Connor and colleagues (2009), who demonstrated in an animal model that peripheral LPS administration activates IDO and produces behavioral depressive-like states measurable by standardized tests. When IDO was pharmacologically blocked or genetically deleted, the LPS-induced depression was prevented — without altering the LPS-induced sickness response, confirming that the depression and sickness are mechanistically distinct and that IDO is the specific gateway to the mood-disrupting pathway.</p><blockquote>O’Connor JC, et al. LPS-Induced Depressive-Like Behavior Is Mediated by IDO Activation in Mice. Mol Psychiatry. 2009;14:511–522. doi:10.1038/sj.mp.4002148 | PMC2683474</blockquote><blockquote>Hassamal S. Chronic Stress, Neuroinflammation, and Depression. Front Psychiatry. 2023. doi:10.3389/fpsyt.2023.1130989 | PMC10213648</blockquote><h4>The Hidden Noses in Your Body: Ectopic Olfactory Receptors as Environmental Sentinels</h4><p>The discovery that olfactory receptors are not confined to the nasal epithelium is one of the most consequential — and least clinically disseminated — findings in recent biomedical science. We have olfactory receptors in the gut, the kidneys, the cardiovascular system, immune cells, skin, the testes, the liver, and the brain. They are expressed throughout the body, and they are active.</p><p>Humans have approximately 400 functional olfactory receptor genes. These receptors are G-protein coupled receptors (GPCRs) — the same receptor superfamily responsible for the majority of pharmacological drug targets — with the distinctive property of high-affinity binding to a wide range of molecular ligands. When expressed ectopically, outside the nose, they retain this binding capability. They become chemosensors for the molecular environment of whatever tissue they inhabit.</p><p><strong>Ectopic ORs in the Gut: The Enterochromaffin Connection</strong></p><p>In the gastrointestinal tract, olfactory receptors are expressed on enterochromaffin cells and enteroendocrine L cells — two of the most functionally critical cell populations in the gut. Enterochromaffin cells produce approximately 90% of the body’s serotonin. Enteroendocrine L cells produce glucagon-like peptide-1 (GLP-1), which regulates glucose homeostasis, appetite, and has emerging roles in neuroprotection.</p><p>The two most studied gut-expressed olfactory receptors in humans are OR51E1 and OR51E2. Research has established that OR51E1 co-localizes with 96% of enterochromaffin cells containing serotonin and 85% of those containing PYY. OR51E2 (the human ortholog of the mouse receptor Olfr78) is the highest-expressed olfactory receptor gene in the human colon, and it responds to the microbially-derived short-chain fatty acids acetate and propionate.</p><p>The significance of this cannot be overstated: the gut’s serotonin-producing cells are regulated in part by receptors that are activated by microbial metabolites. When dysbiosis depletes butyrate-, acetate-, and propionate-producing bacteria — as it characteristically does in SIBO — these ectopic olfactory receptors on enterochromaffin cells are deprived of their primary endogenous ligands. The consequence is impaired enterochromaffin cell differentiation, reduced serotonin signaling capacity, and increased intestinal inflammatory tone. The microbial community and the gut’s neuroendocrine machinery are in direct molecular dialogue — a dialogue that dysbiosis interrupts.</p><blockquote>Colombo M, et al. OR51E1 Is Present along the GI Tract, Co-Localizes with Enteroendocrine Cells and Is Modulated by Intestinal Microbiota. PLOS ONE. 2015;10(6):e0129501. doi:10.1371/journal.pone.0129501 | PMC4468170</blockquote><blockquote>Blache V, et al. The Olfactory Receptor Olfr78 Promotes Differentiation of Enterochromaffin Cells in the Mouse Colon. EMBO Reports. 2024. doi:10.15252/embr.202357241 | PMC10897383</blockquote><blockquote>Braun T, et al. Enterochromaffin Cells of the Human Gut: Sensors for Spices and Odorants. Gastroenterology. 2007;132(5):1890–1901. doi:10.1053/j.gastro.2007.02.036. PMID:17484882</blockquote><p><strong>Environmental Chemicals as Disruptive OR Ligands</strong></p><p>Ectopic olfactory receptors are high-affinity binding sites. This means they are not selective only for their endogenous, microbiome-derived ligands. They can be activated — or competitively blocked — by a wide range of exogenous molecular signals: synthetic fragrances, airborne chemical pollutants, pesticide residues, endocrine-disrupting compounds, and food-derived flavor chemicals that enter circulation after digestion.</p><p>A 2024 review in Life documents that ectopic OR functions may provide crucial insight into how exposure to pollutants and toxic chemicals disrupts the mammalian hormonal and metabolic milieu. When synthetic chemicals competitively displace the short-chain fatty acids that normally activate OR51E2 on colonic enterochromaffin cells, the consequence is functionally equivalent to the effect of dysbiosis: serotonin release is impaired, gut barrier integrity is compromised, and inflammatory tone increases.</p><p>This represents a genuinely novel clinical insight: a person with adequate gut microbial production of acetate and propionate may nonetheless experience ectopic OR disruption if their chemical environment is sufficiently contaminated with competitive OR ligands. The mechanism of action is indistinguishable at the cellular level from the disruption caused by dysbiosis itself.</p><blockquote>Role of Ectopic Olfactory Receptors in the Cardiovascular-Kidney-Metabolic Axis. Life. 2024;14(5):548. doi:10.3390/life14050548 | PMC11122380</blockquote><blockquote>Bienenstock J, et al. Disruptive Physiology: Olfaction and the Microbiome-Gut-Brain Axis. Biological Reviews. 2018;93(1):390–403. doi:10.1111/brv.12348. PMID:28675687</blockquote><h4>You Can Smell Someone Else’s Stress: Social Chemosignals and the Gut</h4><p>Among the most remarkable findings assembled in this article is the following: the stress state of other people can enter your body through your olfactory system, activate your amygdala, elevate your cortisol, and — through the cortisol-tight junction pathway detailed below — directly compromise your gut barrier.</p><p>This is not speculative. It is peer-reviewed and it has been replicated.</p><h4>The Evidence for Social Chemosignaling</h4><p>Research across multiple independent laboratories has demonstrated that <strong>humans emit volatile chemosignals during states of emotional stress and fear</strong> that are chemically distinct from exercise-produced sweat. These signals are detected by recipients below the threshold of conscious awareness — they are processed not as odors in the conventional sense but through specialized receptor systems and neurological pathways associated with social and emotional processing.</p><p>Mujica-Parodi and colleagues (2009) conducted a landmark fMRI study in which participants were exposed to sweat samples collected from individuals undergoing acute psychological stress versus identical individuals during exercise. The stress sweat — but not the exercise sweat — produced significant activation of the left amygdala in recipients, a brain region critically involved in threat detection, emotional memory, and HPA axis regulation. The effect was replicated. It was not explained by perceived odor differences: the two sweat types were rated as equally intense in a forced-choice discrimination task.</p><p>A 2025 study in Communications Chemistry (Nature publishing group) demonstrated that exposure to anxiety chemosignals significantly increases olfactory sensitivity in recipients, with a proposed mechanism involving amygdala activation driving elevated salivary cortisol — cortisol that has been independently shown to modulate HPA axis responsivity and gut permeability.</p><blockquote>Mujica-Parodi LR, et al. Chemosensory Cues to Conspecific Emotional Stress Activate Amygdala in Humans. PLOS ONE. 2009;4(7):e6415. doi:10.1371/journal.pone.0006415 | PMC2713432</blockquote><blockquote>Enhanced Sensitivity to Odors Due to Chemosignals Associated with Anxiety. Communications Chemistry. 2025. doi:10.1038/s42004–025–01512–3</blockquote><p><strong>The Route from Amygdala Activation to Gut Dysbiosis</strong></p><p>Amygdala activation in response to stress chemosignals initiates corticotropin-releasing factor (CRF) release from the hypothalamus, which drives ACTH release from the anterior pituitary, which drives cortisol release from the adrenal cortex — the classical HPA axis cascade. The gut consequences of this cascade are direct and measurable.</p><p>Elevated cortisol increases intestinal permeability by disrupting the tight junction proteins that maintain the gut epithelial barrier. It promotes the proliferation of pathogenic bacteria while depleting beneficial Bifidobacterium and Lactobacillus species. It activates mast cells in the gut mucosa, further increasing permeability through mast cell-derived mediators. And it activates the SNS-mediated release of catecholamines into the gut lumen — catecholamines that certain bacteria can use as growth signals, selectively feeding pathogenic species.</p><p>The clinical evidence is sobering in its specificity. Research by Bailey and colleagues found that even a single brief laboratory speech stressor increased intestinal permeability in healthy adults — and that this effect was present only in individuals with elevated cortisol responses. A separate study found that couples in hostile relationships had measurably greater gut permeability than less hostile couples. <strong>The psychosocial environment is a gastrointestinal variable.</strong></p><blockquote>Psychosocial Stress and the Gut Microbiome: Implications for Inflammation and Immune Modulation. J Appl Physiol. 2025. doi:10.1152/japplphysiol.00652.2024</blockquote><blockquote>Kris-Etherton PM, et al. Stress, Depression, Diet, and the Gut Microbiota. Prog Cardiovasc Dis. 2020;65:88–95. doi:10.1016/j.pcad.2020.04.001 | PMC7213601</blockquote><blockquote>Dangers of Chronic Stress Response in the Microbiota-Gut-Immune-Brain Axis. Front Psychiatry. 2024. doi:10.3389/fpsyt.2024.1352295 | PMC11096445</blockquote><h4>The Integrated Cascade: Assembling the Full Pathway</h4><p>The four mechanisms described above — FODMAP/histamine dysregulation, kynurenine pathway hijacking, LPS-mediated IDO activation, ectopic OR disruption, and social stress chemosignaling — are not independent. They are convergent arms of the same fundamental process, and they compound one another in clinical reality.</p><blockquote>A person walks into a room where others are under chronic stress. Without conscious detection of any odor, their amygdala activates. Cortisol rises. Tight junctions loosen. LPS translocates into circulation. TLR4 fires. IL-6 and TNF-α are released. IDO is induced. Tryptophan — already partially shunted away from serotonin due to SIBO — is now further diverted toward quinolinic acid. Meanwhile, reduced butyrate production from dysbiosis has already been under-stimulating OR51E2 on enterochromaffin cells, impairing serotonin release from the gut. The person eats a nutritionally exemplary meal of garlic, legumes, and spinach. The garlic and legumes ferment in the wrong location, feeding bacterial overgrowth. The spinach delivers histamine that a DAO-depleted gut cannot clear. Mood worsens. The patient concludes the healthy food is the problem. The clinician, without this framework, agrees.</blockquote><p>This cascade, when written out as above, reveals something important: any one of these entry points, activated persistently, will eventually involve all the others. Dysbiosis begets leaky gut begets LPS begets IDO activation begets serotonin depletion begets mood disruption begets behavioral changes that — through stress-mediated catecholamine release, altered food choices, and disrupted sleep — further feed dysbiosis. The loop is self-reinforcing.</p><p>Social chemosignals do not require sustained exposure to operate. A single acute activation of the HPA axis via stress, sweat, or environmental toxins can begin the cascade. <strong>Chronic low-level exposure — as in a stressful workplace, a high-conflict household, or a chemically dense urban environment — maintains it continuously</strong>.</p><h4>Biochemical Individuality: Why the Same Environment Doesn’t Produce the Same Result</h4><p>A framework this mechanistically rich must also account for its most clinically obvious variable: two people can eat the same meal, work in the same office, and share the same chemical environment — and one will spiral into mood dysregulation while the other remains unaffected.</p><p>The answer lies in biochemical individuality — the ANIS framework’s foundational principle. At least four layers of individual variation determine susceptibility:</p><ol><li><strong>Microbial composition: </strong>The specific bacterial community present determines the degree to which LPS is produced, SCFA signaling is intact, DAO activity is maintained, and tryptophan is metabolized toward serotonin versus kynurenine. Two people may have dramatically different microbial profiles despite similar diets and similar environments.</li><li><strong>Genetic polymorphisms in IDO expression: </strong>Individual differences in IDO1 gene expression and enzymatic activity determine how aggressively tryptophan is diverted to kynurenine in response to inflammatory signals. High-IDO individuals are neurochemically vulnerable to even moderate dysbiosis; low-IDO individuals may tolerate significant inflammation without measurable serotonin depletion.</li><li><strong>DAO enzyme activity: </strong>Genetically and environmentally influenced DAO activity determines individual histamine clearance capacity. The same fermented food may be well-tolerated by one patient and dramatically mood-disrupting in another, based solely on this enzyme’s functional status.</li><li><strong>Intestinal permeability baseline: </strong>Prior antibiotic exposure, birth mode (vaginal vs. cesarean), early infant feeding practices, and accumulated stress exposure all influence baseline tight junction integrity — determining how readily LPS translocates into circulation under stress.</li></ol><p>This is precisely the clinical terrain in which generic protocols fail and individualized assessment becomes essential. A universal probiotic, a blanket low-histamine diet, or a single antimicrobial protocol may help one patient dramatically and harm another. The ANIS methodology — applied to aromatic neuromodulation — operates from this same foundational principle: the intervention must match the individual’s specific biochemical terrain, not a population average.</p><h4>Therapeutic Dysphoria: When Getting Better First Feels Worse</h4><p>Clinicians working in gut restoration — whether through dietary interventions, antimicrobial protocols, essential oil-based microbiome modulation, or probiotic reseeding — regularly encounter a phenomenon that has no accepted clinical name but an entirely documentable mechanism: <strong>patients feel emotionally worse in the initial weeks of treatment, precisely when the intervention appears to be working.</strong></p><p>This is not treatment failure. It is an expected biochemical event. When bacterial populations — particularly Gram-negative bacteria — are disrupted or lysed by antimicrobial or aromatic interventions, their outer membranes release LPS into the gut lumen. Even a fraction of this LPS that translocates into circulation before the compromised tight junctions have had time to repair is sufficient to transiently activate TLR4, elevate IL-6, and induce IDO — temporarily further shunting tryptophan away from serotonin at exactly the moment when the patient most needs reassurance that the treatment is working.</p><p>The Chojnacki SIBO treatment studies offer indirect support for this mechanism: rifaximin-treated patients showed improvement in kynurenine pathway metabolites and mood scores — but this improvement unfolded over three months of cyclic treatment, not days. The initial disruption of bacterial communities likely preceded the restoration of pathway balance.</p><p>This clinical reality has significant implications for essential oil-based antimicrobial protocols. <strong>Constituents such as thymol, carvacrol, eugenol, and specific monoterpenes with documented antibacterial activity against Gram-negative bacteria may produce transient mood worsening as bacterial die-off temporarily increases LPS burden before gut healing reduces systemic endotoxemia</strong>. Naming this phenomenon for patients — validating it as a biochemically expected, mechanistically understood event — dramatically improves treatment adherence and prevents premature abandonment of effective protocols.</p><h4>Aromatic Interventions and the Olfactory Axis: The ANIS Clinical Perspective</h4><p>If ectopic olfactory receptors are active chemosensors throughout the body — including in the gut — and if they are disrupted by both dysbiosis and environmental chemical exposure, then aromatic compounds delivered in pharmacologically appropriate forms may represent a restoration strategy with a uniquely direct mechanism of action.</p><p><strong>This is distinct from — and must not be conflated with — conventional aromatherapy</strong>. The mechanism in question is not mood influence through limbic activation from a pleasant scent. It is a constituent-specific interaction with ectopic olfactory receptors and their downstream GPCR signaling pathways in gut epithelium, immune tissue, and vascular endothelium.</p><p><strong>What the Evidence Supports</strong></p><p>Specific essential oil constituents have been shown to interact with the kynurenine pathway and inflammatory cascades relevant to this discussion.</p><ul><li>Anti-inflammatory constituents that reduce IL-6 and TNF-α would be expected to reduce IDO induction — preserving tryptophan for serotonin synthesis.</li><li>Constituents with documented antimicrobial activity against LPS-bearing Gram-negative bacteria reduce the endotoxin burden, driving the cascade.</li><li>Constituents that modulate vagal tone may support gut barrier integrity via the autonomic nervous system.</li><li>Specific constituents — including some terpenes and phenylpropanoids — have demonstrated direct interaction with gut olfactory receptors and enteroendocrine cell signaling.</li></ul><p>Critically, the specificity of the intervention matters. The ANIS™️ methodology’s insistence on constituent-level analysis rather than generic oil recommendations reflects not aesthetics but biochemical necessity. OR51E2 has a ligand profile that includes short-chain fatty acid homologs. Competitive agonism or antagonism at this receptor requires knowing which constituent is being delivered, at what concentration, and what else may be competing for the binding site in that individual’s specific biochemical environment.</p><p><strong>A Note on Temporality and Patient Communication</strong></p><p>The aromatic intervention timeline in gut restoration contexts should be communicated to patients in terms of the cascade this article has described. Early intervention may modulate the inflammatory environment, but full restoration of OR-mediated enteroendocrine signaling, DAO enzyme activity, tight junction integrity, and kynurenine pathway balance requires a different timeframe at each biological layer. <strong>Expecting emotional improvement before gut microbial diversity has been restored sets an unrealistic bar that leads to premature treatment abandonment.</strong></p><p>The metaphor that serves these patients best may be architectural: you cannot repaint a room while the walls are still wet from the flood. The aromatic protocol addresses inflammation and bacterial balance.</p><p>Microbiome diversity takes months to restore.</p><p>Enterochromaffin cell differentiation follows microbiome stability. Central serotonin availability follows that.</p><p>The emotional experience of the person shifts last — not because the treatment isn’t working, but because it is working in the correct sequence.</p><h4>A Framework for Clinical Practice</h4><p>This article has assembled a cascade that clinicians working at the intersection of digestive health, mental well-being, and integrative medicine increasingly need to articulate. Its core claims are not speculative — they are documented in peer-reviewed clinical trials, mechanistic studies, and chemosensory biology research spanning multiple disciplines.</p><p>The core clinical reframings this framework offers are:</p><ul><li><strong>Mood is a gastrointestinal variable.</strong></li><li>Healthy foods can worsen mood in an unhealthy gut — not because the foods are wrong, but because the ecosystem that processes them has been disrupted.</li><li>Tryptophan availability for serotonin synthesis is regulated by the microbiome, not just diet — and dysbiosis predictably shifts the balance toward neurotoxic kynurenine metabolites.</li><li>The environment — including the stress chemistry of other people — enters the gut through olfactory and cortisol-mediated pathways that operate below conscious awareness.</li><li>Individualized intervention — calibrated to the specific microbial, enzymatic, and olfactory receptor profile of the patient — is not a luxury. It is a biochemical requirement.</li></ul><p>The patient asking, “why do I feel worse when I try to eat better?” deserves an answer. <strong>This</strong> is the answer.</p><h4>References</h4><p><strong>1. </strong>Lin P, et al. Dysbiosis of the Gut Microbiota and Kynurenine (Kyn) Pathway Activity as Potential Biomarkers in Patients with Major Depressive Disorder. Nutrients. 2023;15(7):1752. doi:10.3390/nu15071752</p><p><strong>2. </strong>Wiedłocha M, et al. Gut Microbiota, Kynurenine Pathway and Mental Disorders. Prog Neuro-Psychopharmacol Biol Psychiatry. 2021;106:110145. doi:10.1016/j.pnpbp.2020.110145. PMID:33203568</p><p><strong>3. </strong>Kennedy PJ, et al. Kynurenine Pathway Metabolism and the Microbiota-Gut-Brain Axis. Neurosci Biobehav Rev. 2017;74(Pt B):209–233. doi:10.1016/j.neubiorev.2016.06.032. PMID:27392632</p><p><strong>4. </strong>Kearns R, et al. The Kynurenine Pathway in Gut Permeability and Inflammation. Inflammation. 2025;48(3):1063–1077. doi:10.1007/s10753–024–02135-x. PMC12234587</p><p><strong>5. </strong>Chojnacki C, et al. Altered Tryptophan Metabolism on the Kynurenine Pathway in Depressive Patients with SIBO. Nutrients. 2022;14(15):3217. doi:10.3390/nu14153217. PMC9370164</p><p><strong>6. </strong>Chojnacki C, et al. Antimicrobial Treatment Improves Tryptophan Metabolism and Mood in SIBO Patients. Nutr Metab (Lond). 2022;19:66. doi:10.1186/s12986–022–00700–5. PMC9513933</p><p><strong>7. </strong>Chojnacki C, et al. Changes in Tryptophan Metabolism on Serotonin and Kynurenine Pathways in IBS Patients. Nutrients. 2023;15(5):1262. doi:10.3390/nu15051262. PMC10005076</p><p><strong>8. </strong>O’Connor JC, et al. LPS-Induced Depressive-Like Behavior Is Mediated by IDO Activation in Mice. Mol Psychiatry. 2009;14:511–522. doi:10.1038/sj.mp.4002148. PMC2683474</p><p><strong>9. </strong>Hassamal S. Chronic Stress, Neuroinflammation, and Depression. Front Psychiatry. 2023. doi:10.3389/fpsyt.2023.1130989. PMC10213648</p><p><strong>10. </strong>Neuroinflammation — A Crucial Factor in the Pathophysiology of Depression. Int J Mol Sci. 2025. doi:10.3390/ijms26083784. PMC12024626</p><p><strong>11. </strong>Braun T, et al. Enterochromaffin Cells of the Human Gut: Sensors for Spices and Odorants. Gastroenterology. 2007;132(5):1890–1901. doi:10.1053/j.gastro.2007.02.036. PMID:17484882</p><p><strong>12. </strong>Colombo M, et al. OR51E1 Is Present along the GI Tract, Co-Localizes with Enteroendocrine Cells and Is Modulated by Intestinal Microbiota. PLOS ONE. 2015;10(6):e0129501. doi:10.1371/journal.pone.0129501. PMC4468170</p><p><strong>13. </strong>Blache V, et al. The Olfactory Receptor Olfr78 Promotes Differentiation of Enterochromaffin Cells in the Mouse Colon. EMBO Reports. 2024. doi:10.15252/embr.202357241. PMC10897383</p><p><strong>14. </strong>Yoo S, et al. Activation of Ectopic Olfactory Receptor Olfr544 Induces GLP-1 Secretion and Regulates Gut Inflammation. Mol Metab. 2021. doi:10.1016/j.molmet.2021.101280. PMC8632334</p><p><strong>15. </strong>Role of Ectopic Olfactory Receptors in the Cardiovascular-Kidney-Metabolic Axis. Life. 2024;14(5):548. doi:10.3390/life14050548. PMC11122380</p><p><strong>16. </strong>Bienenstock J, et al. Disruptive Physiology: Olfaction and the Microbiome-Gut-Brain Axis. Biological Reviews. 2018;93(1):390–403. doi:10.1111/brv.12348. PMID:28675687</p><p><strong>17. </strong>Intestinal Fatty Acid-Enteroendocrine Interplay, Emerging Roles for Olfactory Signaling and Serotonin Conjugates. Molecules. 2021;26(5):1416. doi:10.3390/molecules26051416. PMC7961910</p><p><strong>18. </strong>Mujica-Parodi LR, et al. Chemosensory Cues to Conspecific Emotional Stress Activate Amygdala in Humans. PLOS ONE. 2009;4(7):e6415. doi:10.1371/journal.pone.0006415. PMC2713432</p><p><strong>19. </strong>Dalton P, et al. Chemosignals of Stress Influence Social Judgments. PLOS ONE. 2013;8(10):e77144. doi:10.1371/journal.pone.0077144. PMC3793963</p><p><strong>20. </strong>Enhanced Sensitivity to Odors Due to Chemosignals Associated with Anxiety. Commun Chem. 2025. doi:10.1038/s42004–025–01512–3</p><p><strong>21. </strong>Can You Smell My Stress? Stress Chemosignals on Empathy and Emotion Recognition in Depressed Individuals. Physiol Behav. 2023. doi:10.1016/j.physbeh.2023.114370</p><p><strong>22. </strong>Psychosocial Stress and the Gut Microbiome: Implications for Inflammation. J Appl Physiol. 2025. doi:10.1152/japplphysiol.00652.2024</p><p><strong>23. </strong>Kris-Etherton PM, et al. Stress, Depression, Diet, and the Gut Microbiota. Prog Cardiovasc Dis. 2020;65:88–95. doi:10.1016/j.pcad.2020.04.001. PMC7213601</p><p><strong>24. </strong>Signalling Cognition: The Gut Microbiota and HPA Axis. Front Endocrinol. 2023. doi:10.3389/fendo.2023.1130689</p><p><strong>25. </strong>Dangers of Chronic Stress Response in the Microbiota-Gut-Immune-Brain Axis. Front Psychiatry. 2024. doi:10.3389/fpsyt.2024.1352295. PMC11096445</p><p><strong>26. </strong>Stress in the Microbiome-Immune Crosstalk. Gut Microbes. 2024. doi:10.1080/19490976.2024.2327409</p><p><strong>27. </strong>Dietary Treatment of Histamine Intolerance Reduces Histamine-Secreting Bacteria. Front Nutr. 2022. doi:10.3389/fnut.2022.1018463. PMC9633985</p><p><strong>28. </strong>Emerging Role of Olfactory Receptors: From Genomics to Precision Medicine. Mol Diagn Ther. 2025. doi:10.1007/s40291–026–00832-x</p><p><strong>29. </strong>Mechanisms of Activation and Serotonin Release from Human Enterochromaffin Cells. Cell Mol Gastroenterol Hepatol. 2025. doi:10.1016/j.jcmgh.2025.101479</p><p><em>© Aromagenomics. All rights reserved. This article is intended for educational purposes and professional development. It does not constitute medical advice. Portions may be reproduced with attribution.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=d334e6d42787" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Why your childhood might be the strongest predictor of how you grieve…]]></title>
            <link>https://tammylynndavis.medium.com/why-your-childhood-might-be-the-strongest-predictor-of-how-you-grieve-935c2acc94e2?source=rss-bea04f141334------2</link>
            <guid isPermaLink="false">https://medium.com/p/935c2acc94e2</guid>
            <category><![CDATA[self-improvement]]></category>
            <category><![CDATA[integrative-medicine]]></category>
            <category><![CDATA[grief]]></category>
            <category><![CDATA[mental-health]]></category>
            <category><![CDATA[self-love]]></category>
            <dc:creator><![CDATA[Tammy Lynn Davis]]></dc:creator>
            <pubDate>Tue, 17 Feb 2026 21:07:37 GMT</pubDate>
            <atom:updated>2026-02-17T21:07:37.638Z</atom:updated>
            <content:encoded><![CDATA[<h4>…the hidden connection between early trauma &amp; prolonged grief</h4><figure><img alt="" src="https://cdn-images-1.medium.com/max/884/1*Zva4I8qrew4EaP8bYQn8dg.jpeg" /></figure><p><em>Have you ever wondered why some people seem to integrate loss gracefully while others remain stuck in grief years later? New research reveals it might have less to do with the loss itself — and more to do with what happened decades before it.</em></p><p>I’ve invested nearly 40 years in neuroscience, trauma, and the chemistry of essential oils. And what I’ve learned — both from research and from sitting with hundreds of grieving individuals — is that the way you grieve today was largely written into your nervous system before you turned five years old.</p><p>This isn’t meant to discourage you. It’s meant to free you.</p><p>Because when you understand WHY your grief feels the way it does, you can finally stop fighting yourself and start working with your nervous system instead of against it.</p><h4>The Research That Changed Everything</h4><p>A recent study using machine learning to predict prolonged grief disorder made a startling discovery: <strong>childhood trauma was the strongest predictor of grief severity</strong> — stronger than the nature of the loss, stronger than the closeness of the relationship, stronger than any current life circumstances.</p><p>Let that sink in.</p><p>It wasn’t whether you lost a spouse or a parent. It wasn’t whether the death was sudden or expected. It wasn’t even how close you were to the person who died.</p><p><strong>The strongest predictor was what happened to you as a child.</strong></p><p>This finding fundamentally challenges how we think about grief. We’ve been asking the wrong questions. Instead of “What’s wrong with me?” or “Why is it so hard for me to feel better?”, the more useful question is: “What is my nervous system protecting me from?” (<em>if you don’t understand the thinking behind this last question … don’t worry…you will shortly</em>)</p><h4>Why This Matters (And What It Actually Means)</h4><p>Your nervous system developed its template for handling overwhelming experiences in childhood. This isn’t metaphorical — it’s <strong>neurobiological</strong>. The neural pathways for emotional regulation, stress response, and relationship repair were literally being wired during your early years, shaped by your environment.</p><p>If your early environment was:</p><ul><li><strong>Unpredictable</strong> → You developed hypervigilance as a survival strategy</li><li><strong>Emotionally barren</strong> → You learned to suppress your needs because expressing them didn’t work</li><li><strong>Dangerous or frightening</strong> → You learned to shut down or dissociate to protect yourself</li><li><strong>Inconsistently responsive</strong> → You learned to amplify emotions to increase the odds of getting attention</li></ul><p>When a significant loss happens in adulthood, your nervous system doesn’t create a new response from scratch. It reverts to these deeply wired childhood patterns because they’re your brain’s default program for “overwhelming situation.”</p><p>This is why:</p><ul><li>Some people can’t stop crying (anxious attachment — learned to amplify to get needs met)</li><li>Some people can’t cry at all (avoidant attachment — learned emotions were unwelcome or overwhelming to others)</li><li>Some people oscillate wildly between extremes (disorganized attachment — never found a strategy that worked consistently)</li></ul><p><strong>None of these responses are character flaws. They’re survival strategies your nervous system developed when you were small and had limited options.</strong></p><h4>The Four Patterns and What They Mean for Your Grief</h4><p>Understanding your pattern isn’t about labeling yourself — it’s about recognizing why your nervous system does what it does so you can work with it instead of against it.</p><p><strong>Anxious Attachment in Grief</strong></p><p>If you had caregivers who were inconsistently available — sometimes responsive, sometimes not — you learned to amplify your emotional expressions to increase the likelihood of getting attention. As a child, this was adaptive: crying louder, showing more distress, or clinging more intensely sometimes worked to bring the caregiver closer.</p><p><strong>In adult grief, this shows up as:</strong></p><ul><li>Intense, overwhelming waves of emotion that feel uncontrollable</li><li>Difficulty being alone with your grief</li><li>Constant need to talk about the loss</li><li>Fear that if you stop actively grieving, you’ll forget the person</li><li>Panic that others will leave if you’re not visibly suffering</li></ul><p><strong>What your nervous system needs:</strong> Not to suppress these feelings, but to learn that you can tolerate the intensity without it destroying you. Your work is building capacity to stay with difficult emotions without needing external regulation from others. This doesn’t mean you shouldn’t reach out for support — it means learning that you have internal resources too.</p><p><strong>Avoidant Attachment in Grief</strong></p><p>If you had caregivers who were consistently unavailable, dismissive, or overwhelmed by emotion, you learned to shut down your emotional expression. As a child, this kept you safe: showing need or distress made things worse, so you learned to handle everything internally.</p><p><strong>In adult grief, this shows up as:</strong></p><ul><li>Numbness or inability to cry even when you want to</li><li>Intellectualizing the loss rather than feeling it</li><li>Staying extremely busy to avoid confronting the grief</li><li>Feeling like you “should” be more upset than you are</li><li>Physical symptoms (headaches, digestive issues, chronic pain) because emotions are somatized</li></ul><p><strong>What your nervous system needs:</strong> Permission to feel without judgment. Your shutdown response isn’t coldness or lack of love — it’s a protective mechanism that was once essential. Your work is slowly building tolerance for emotional experience in small, manageable doses. You’re not trying to “open the floodgates” — you’re learning that feelings won’t destroy you or others.</p><p><strong>Disorganized Attachment in Grief</strong></p><p>If you had caregivers who were the source of both comfort and fear — perhaps loving at times but frightening at others, or well-meaning but overwhelmed and unpredictable — you never developed a coherent strategy for handling distress. Approach and avoidance were both necessary and both dangerous.</p><p><strong>In adult grief, this shows up as:</strong></p><ul><li>Oscillating between flooding and numbing with no middle ground</li><li>Feeling completely out of control emotionally</li><li>Difficulty making sense of your own reactions</li><li>Simultaneous desire for connection and terror of it</li><li>Dissociation or feeling disconnected from your own experience</li></ul><p><strong>What your nervous system needs:</strong> Safety and predictability first, emotional exploration second. Your nervous system learned that there’s no winning strategy, so it cycles through all of them. Your work is building a felt sense of safety that allows you to stay present with your experience without fragmenting. This often requires professional support because the nervous system needs to learn it’s safe to have an organized response.</p><p><strong>Secure Attachment in Grief (Yes, It Still Hurts)</strong></p><p>If you had caregivers who were consistently available and attuned to your needs, you learned that emotions are manageable, that seeking support works, and that you can return to equilibrium after distress.</p><p><strong>In adult grief, this shows up as:</strong></p><ul><li>Ability to feel deeply sad without becoming overwhelmed or shut down</li><li>Natural oscillation between grieving and functioning</li><li>Capacity to seek and accept support</li><li>Ability to hold complexity (missing someone while building a new life)</li><li>Gradual integration of the loss over time</li></ul><p><strong>Important note:</strong> Having secure attachment doesn’t make grief less painful — it makes it more workable. You’ll still have hard days, but your nervous system knows how to move through them.</p><h4>The Emotion Regulation Bridge</h4><p>Here’s what the research shows is happening: childhood trauma doesn’t directly cause prolonged grief — it causes difficulties with emotion regulation, and <em>those difficulties</em> then lead to complicated grief.</p><p>This is crucial because it tells you where to focus your efforts.</p><p>If you struggle with emotion regulation — meaning you either get overwhelmed by feelings or can’t access them at all — that’s what needs support. Not your grief specifically, but your capacity to be with difficult emotions in general.</p><p><strong>This is why “just feel your feelings” doesn’t work if no one taught you how to feel feelings in the first place.</strong></p><p>You can’t feel your way through something if you never developed the neural infrastructure for tolerating intense emotion. It’s like telling someone to run a marathon when they never learned to walk properly — the instruction isn’t wrong, but developmental steps are missing.</p><h4>What Actually Helps (Working With Your Pattern)</h4><p>Understanding your pattern tells you what your nervous system needs:</p><p><strong>If you have anxious attachment:</strong></p><ul><li>Practice grounding techniques that help you tolerate intensity without needing external regulation</li><li>Build capacity for being alone with your grief in small, titrated doses</li><li>Use essential oils that support parasympathetic activation (ylang ylang, vetiver, frankincense) to help downregulate when flooding occurs</li><li>Recognize that your intense emotions don’t mean something is wrong — your nervous system is doing what it learned to do</li></ul><p><strong>If you have avoidant attachment:</strong></p><ul><li>Give yourself permission to feel in private, safe spaces where you won’t be judged</li><li>Start with body sensations rather than trying to access emotions directly (”I notice tension in my chest” rather than “I should feel sad”)</li><li>Use essential oils that support emotional access without overwhelming (rose, galbanum, grapefruit)</li><li>Recognize that your numbness doesn’t mean you didn’t love them — your nervous system is protecting you the only way it knows how</li></ul><p><strong>If you have disorganized attachment:</strong></p><ul><li>Prioritize nervous system regulation before emotional processing</li><li>Work with a trauma-informed therapist who understands attachment</li><li>Use essential oils that support felt safety and grounding (cedarwood atlas, rosemary verbenone, myrrh)</li><li>Recognize that your chaotic responses make sense given what your nervous system learned</li></ul><p><strong>If you have secure attachment:</strong></p><ul><li>Trust your natural grief process even when it’s painful</li><li>Continue using your existing support systems</li><li>Use essential oils for comfort rather than regulation (whatever brings you solace)</li><li>Recognize that even with secure attachment, some losses will temporarily destabilize you — and that’s normal</li></ul><h4>The Perspective Shift That Changes Everything</h4><p>Here’s the transformation I want to offer you:</p><p><strong>Your grief isn’t “wrong.” Your grief is revealing the template your nervous system created decades ago.</strong></p><p>When you stop pathologizing your grief response and start seeing it as information about what your nervous system learned, everything changes. You move from shame (”Why can’t I just get over this?”) to curiosity (”What is my nervous system trying to protect me from?”).</p><p><strong>This doesn’t mean your childhood determines your destiny</strong>. Attachment patterns increase risk but don’t determine outcome. Many people with difficult childhoods grieve in healthy, integrated ways.</p><p>What makes the difference is awareness and targeted support that matches your actual nervous system needs rather than generic grief advice.</p><h4>When You Need More Than Understanding</h4><p>Understanding your pattern is powerful, but sometimes understanding alone isn’t enough. You might need professional support if you:</p><ul><li>Feel like you’re getting worse rather than better over time</li><li>Can’t function in basic daily activities for extended periods</li><li>Have thoughts of harming yourself</li><li>Notice your grief is preventing you from any meaningful connection</li><li>Experience flashbacks or trauma symptoms alongside grief</li><li>Feel completely disconnected from your own experience</li></ul><p>This isn’t failure — it’s recognizing that some nervous system patterns need professional rewiring, especially if trauma was severe or occurred very early in development.</p><p>Look for therapists trained in:</p><ul><li>Attachment-based therapy</li><li>EMDR (Eye Movement Desensitization and Reprocessing)</li><li>Somatic Experiencing</li><li>Internal Family Systems (IFS)</li><li>Sensorimotor Psychotherapy</li></ul><p>These modalities work directly with the nervous system and early attachment patterns rather than just talking about grief.</p><h4>Why Essential Oils?</h4><p>You might wonder why I keep mentioning essential oils in the context of attachment and grief. Here’s the neuroscience: <strong>aromatic molecules travel directly to the limbic system</strong> — the part of your brain where attachment patterns, emotional memories, and stress responses are encoded.</p><p>This is the same neural territory where your childhood patterns were wired. Essential oils can’t “fix” your attachment pattern, but <strong>they can support nervous system regulation while you do the deeper work</strong>. They’re particularly useful because they bypass the cortex (your thinking brain) and work directly with the subcortical structures that govern emotional experience.</p><blockquote><em>This isn’t about replacing therapy or inner work — it’s about giving your nervous system additional support while you’re learning new patterns.</em></blockquote><h4>Moving Forward</h4><p>Your grief is not evidence of weakness, pathology, or insufficient healing. Your grief is your nervous system using the only template it has for overwhelming experience — the one that was created when you were small.</p><p>Understanding this doesn’t make the pain go away. But it can transform your relationship with that pain.</p><p>Instead of fighting against yourself, you can work with your nervous system. Instead of shame about “not grieving right,” you can have compassion for the patterns that once kept you safe.</p><p>And that shift — from fighting to understanding, from shame to compassion — is often the beginning of genuine transformation.</p><p><strong>For those who want to go deeper:</strong> I’ve created a comprehensive report (<em>Childhood Trauma, Attachment &amp; Prolonged Grief: The Neuroscience of Why We Get Stuck and How to Move Forward</em>) that includes detailed assessment tools, specific essential oil protocols for each attachment pattern, complete clinical references, and decision frameworks for when professional support is needed. It’s available to paid subscribers, but this article contains the core perspective shift that changes how you understand your own grief.</p><p><em>Coming soon: “The Three Nervous System States of Grief (And Why You Need to Know Which One You’re In)”</em></p><p>© 2026 Tammy Davis | Aromagenomics <a href="https://calendly.com/tammy-aromagenomics/30min"><strong>Schedule your discovery call for a more personalized approach.</strong></a></p><p><em>This post is for educational purposes only and does not constitute medical or mental health advice.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=935c2acc94e2" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>